CD3 antigen-binding fragments and uses thereof
Humanized anti-CD3 antibodies with specific CDR and framework sequences address HAMA reactions and enhance therapeutic efficacy by improving affinity and stability, enabling effective targeting of CD3 and tumor antigens.
Patent Information
- Application Number
- JP2023070901
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-04-24
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2039-02-22
AI Technical Summary
Existing anti-CD3 antibodies, such as murine-derived antibodies, cause HAMA reactions in humans and face challenges like decreased affinity, stability, and yield during humanization, limiting their therapeutic effectiveness.
Development of humanized antibodies with specific amino acid sequences in the CDRs and framework regions that bind to CD3 in humans and primates, along with multispecific antibodies targeting tumor antigens and immune cells, enhancing affinity, stability, and biological activity.
The humanized antibodies demonstrate comparable affinity, improved biological activity, and enhanced thermal and acid resistance, making them effective for therapeutic applications with reduced side effects.
Smart Images

Figure 0007595696000098 
Figure 0007595696000099 
Figure 0007595696000100
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of genetic engineering, in particular to the field of antibody engineering. In particular, the present invention relates to antibodies, such as multifunctional antibodies, such as antibodies against CD3, in particular humanized antibodies, antigen-binding fragments of said antibodies and related uses. [Background technology]
[0002] CD3 is a T cell surface molecule that can bind to the T cell receptor on the surface of T cells to form a TCR-CD3 complex and activate T cells. It plays an important role in antigen recognition and immune signal transduction. Anti-CD3 antibodies are widely used in the treatment of transplant rejection, autoimmune diseases, etc. It is known that murine anti-CD3 antibodies such as OKT3 may have caused HAMA (human anti-mouse antibody) reactions and are not suitable for use in humans. Therefore, it is necessary to humanize or otherwise process these murine antibodies to reduce side effects. Traditionally, the main route to avoid or reduce HAMA reactions is to humanize murine monoclonal antibodies or develop fully humanized antibodies. For example, HAMA reactions can be reduced by introducing sequence fragments similar to human antibody proteins into murine antibodies. However, structurally similar proteins may not exist in humans, so such processing may not be possible. Furthermore, antibody humanization often encounters technical difficulties such as reduced antibody affinity, reduced vitality, reduced stability, or reduced yield, which often results in an ineffective therapeutic protein. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] WO2013 / 158856 [Patent Document 2] WO2007 / 019620 [Patent Document 3] WO2017 / 023761 Summary of the Invention [Problem to be solved by the invention]
[0004] The present invention provides antibodies, eg, multifunctional antibodies, eg, antibodies against CD3, particularly humanized antibodies, antigen-binding fragments of said antibodies, and related uses. [Means for solving the problem]
[0005] In some embodiments, the present invention provides an antibody or antigen-binding fragment thereof, particularly a humanized antibody or antigen-binding fragment thereof, comprising: specifically binds to CD3 of humans and / or primates such as monkeys, framework regions FR-H1, FR-H2, FR-H3, FR-H4, FR-L1, FR-L2, FR-L3 and FR-L4, and complementarity determining regions (CDRs); the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of the heavy chain variable region are the amino acid sequences shown in SEQ ID NOs: 1, 2 and 3, respectively, or mutant sequences thereof, for example, any one of the sequences shown in SEQ ID NOs: 4-14 and 190-191, which are mutant sequences of CDR-H3; the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 of the light chain variable region are the amino acid sequences shown in SEQ ID NOs: 26, 27, and 28, respectively, or mutant sequences thereof; The framework region of the humanized antibody comprises: a) FR-H1 of SEQ ID NO: 15 or 16 b) FR-H2 of SEQ ID NO: 17 c) FR-H3 of any one of SEQ ID NOs: 18-24 d) FR-H4 of SEQ ID NO: 25 e) FR-L1 of any one of SEQ ID NOs: 29-31 f) FR-L2 of any one of SEQ ID NOs: 32-38 g) FR-L3 of any one of SEQ ID NOs: 39-42, and / or h) FR-L4, any one of SEQ ID NOs: 43-44 An antibody or antigen-binding fragment thereof comprising one or more sequences selected from the group consisting of:
[0006] In some embodiments, the present invention provides an antibody or antigen-binding fragment thereof, particularly a humanized antibody or antigen-binding fragment thereof, comprising: specifically binds to CD3 of humans and / or primates such as monkeys, comprising a heavy chain variable region and a light chain variable region, The heavy chain variable region a) the amino acid sequence of SEQ ID NO: 45-62; b) an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one amino acid sequence of SEQ ID NO: 45-62, and c) an amino acid sequence which has one or more (preferably one or several, more preferably one, two or three) amino acids which differ from at least one of the amino acid sequences of SEQ ID NOs: 45-62; Any one sequence selected from the group the light chain variable region d) the amino acid sequence of SEQ ID NO: 63-73; e) an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one amino acid sequence of SEQ ID NO: 63-73, and f) an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of the amino acid sequences of SEQ ID NOs: 63-73; An antibody or an antigen-binding fragment thereof comprising any one of the sequences selected from the group consisting of:
[0007] In some embodiments, the present invention provides an antibody or antigen-binding fragment thereof, particularly a humanized antibody or antigen-binding fragment thereof, comprising: specifically binds to CD3 of humans and / or primates such as monkeys, comprising a heavy chain variable region and a light chain variable region, The heavy chain variable region and the light chain variable region each comprise: a) SEQ ID NO:46, 63; SEQ ID NO:47, 63; SEQ ID NO:49, 63; SEQ ID NO:50, 63; SEQ ID NO:51, 63; SEQ ID NO:46, 71; SEQ ID NO:47, 71; SEQ ID NO:49, 71; SEQ ID NO:51, 71; SEQ ID NO:52, 72; SEQ ID NO:53, 72; SEQ ID NO:54, 72; SEQ ID NO:55, 72; SEQ ID NO:56, 72; SEQ ID NO:57, 72; SEQ ID NO:58, 72; SEQ ID NO:62, 72; SEQ ID NO:52, 73; SEQ ID NO:53, 73; SEQ ID NO: 54, 73;SEQ ID NO:55, 73;SEQ ID NO:56, 73;SEQ ID NO:57, 73;SEQ ID NO:58, 73;SEQ ID NO:61, 73;SEQ ID NO:62, 73;SEQ ID NO:45, 63;SEQ ID NO:48, 63;SEQ ID NO:45, 64;SEQ ID NO:45, 67;SEQ ID NO:48, 64;SEQ ID NO:48, 67;SEQ ID NO:45, 71;SEQ ID NO:48, 71;SEQ ID NO:50, 71;SEQ ID NO:61, 72;SEQ ID NO:60, 73;SEQ ID NO:60, 72;SEQ ID NO:59, 72 b) an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one amino acid sequence of a); and c) an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of the amino acid sequences of a); An antibody or antigen-binding fragment thereof comprising an amino acid sequence selected from the group consisting of:
[0008] In some embodiments, the present invention provides a multispecific antibody, preferably a bispecific antibody, comprising: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 and an antibody or antigen-binding fragment thereof against another antigen and / or another antigen epitope, A multispecific antibody, wherein the other antigens and / or other antigenic epitopes are, for example, proteins that are overexpressed on tumor cells compared to corresponding non-tumor cells; tumor antigens, such as CD38, BCMA, PD-L1, SLAMF7, Claudin 18.2 or CEA; viruses; bacteria; and / or endotoxins.
[0009] In some embodiments, the present invention provides: a polypeptide, the amino acid sequence of which comprises or is selected from the amino acid sequence of any one of SEQ ID NOs: 45-62, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity to at least one amino acid sequence of SEQ ID NOs: 45-62, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one amino acid sequence of SEQ ID NOs: 45-62.
[0010] In some embodiments, the present invention provides: a polypeptide, the amino acid sequence of which comprises or is selected from the amino acid sequence of any one of SEQ ID NOs: 63-73, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity to at least one amino acid sequence of SEQ ID NOs: 63-73, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one amino acid sequence of SEQ ID NOs: 63-73.
[0011] In some embodiments, the humanized antibody has comparable affinity, improved biological activity, thermal stability and / or acid tolerance as compared to a control antibody.
[0012] In some embodiments, the present invention provides a polynucleotide encoding a polypeptide of the present invention.
[0013] In some embodiments, the present invention provides an antibody comprising (a) a light chain-heavy chain pair and (b) a fusion peptide, the light chain-heavy chain pair having specificity for a tumor cell or a microorganism, and the fusion peptide comprising a single chain variable region fragment and a single chain Fc fragment having specificity for an immune cell. In some embodiments, the single chain Fc fragment comprises a CH2 and / or a CH3 as described herein, e.g., a CH2 having the sequence of any one of SEQ ID NOs: 155-161 or 192, and / or a CH3 having the sequence of any one of SEQ ID NOs: 162-183. In some embodiments, the fusion peptide comprises a corresponding sequence or a subsequence thereof of an antibody described herein. For example, the fusion peptide comprises the sequence of the light and / or heavy chain variable region and / or framework region of a humanized antibody described herein. In some embodiments, the single chain variable region fragment (scFv) of the fusion peptide comprises an scFV of a humanized antibody described herein.
[0014] In some embodiments, the fusion peptide in the antibody of the present invention comprises VHs-linker1-VLs-hinge1-CH2-CH3-b, the heavy chain comprises VHm-CH1-hinge2-CH2-CH3-a, and the light chain comprises VLm-CL.
[0015] In some embodiments, the light chain-heavy chain pair in the antibody of the invention specifically binds to a) a protein that is overexpressed on tumor cells compared to corresponding non-tumor cells, b) a tumor antigen, such as CD38, BCMA, PD-L1, SLAMF7, Claudin 18.2 or CEA, c) a virus, d) a bacterium, and / or e) an endotoxin.
[0016] In some embodiments, the fusion peptide of the antibody of the present invention specifically binds to an immune cell antigen. For example, the fusion peptide comprises an antigen-binding site that specifically binds to CD3 of a primate, such as a human and / or monkey. For example, the fusion peptide comprises the variable regions of the light and heavy chains of an antibody described herein.
[0017] In some embodiments, the VH of the fusion peptide in the antibody of the present invention comprises any one of the sequences of SEQ ID NOs: 45-62, 74, 76, 78, 80, 82, 84, 86, 88; the VL of the fusion peptide comprises any one of the sequences of SEQ ID NOs: 63-73, 75, 77, 79, 81, 83, 85, 87, 89; the linker 1 of the fusion peptide comprises any one of the sequences of SEQ ID NOs: 120-138; the hinge 1 of the fusion peptide and the hinge 2 of the heavy chain comprise any one of the sequences of SEQ ID NOs: 139-147; the CH2 of the fusion peptide and the CH2 of the heavy chain comprise any one of the sequences of SEQ ID NOs: 155-161 or 192; 177, 179, 181, 183, and the CH3-a of the heavy chain comprises any one of the sequences of SEQ ID NOs: 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, and the VHm of the heavy chain comprises any one of the sequences of SEQ ID NOs: 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 119, 200, 201, 202, 203, 204, 205, 206, 207, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 250, 251, 252, 253, 254, 255, 256, 257, 258, 260, 261, 262, 263, 264, 265, 266, 268, 270, 272, 274, 276, 278, 280, 282, and 18 or 193, the CH1 of the heavy chain comprises the sequence of SEQ ID NO: 154, the VLm of the light chain comprises the sequence of any one of SEQ ID NOs: 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 194, and / or the CL of the light chain comprises the sequence of any one of SEQ ID NOs: 148-153.
[0018] In some embodiments, the VH and VL of the fusion peptide in the antibody of the present invention each comprise an amino acid sequence selected from the following group: a) SEQ ID NO:45, 63; SEQ ID NO:48, 63; SEQ ID NO:48, 71; SEQ ID NO:49, 63; SEQ ID NO:49, 71; SEQ ID NO:51, 71; SEQ ID NO:58, 72; SEQ ID NO:60, 72; SEQ ID NO:60, 73; SEQ ID NO:59, 72; SEQ ID NO:61, 73; SEQ ID NO:62, 73; SEQ ID NO:58, 72; SEQ ID NO:74, 75; SEQ ID NO:76, 77; SEQ ID NO:78, 79; SEQ ID NO:80, 81; SEQ ID NO:82, 83; SEQ ID NO:84, 85; SEQ ID NO:86, 87; SEQ ID NO:88, 89; b) an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one amino acid sequence of a); and c) an amino acid sequence which has one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of the amino acid sequences of a), and / or The VHm of the heavy chain and the VLm of the light chain each comprise an amino acid sequence selected from the group consisting of: d) SEQ ID NOs: 90, 91; SEQ ID NOs: 92, 93; SEQ ID NOs: 94, 95; SEQ ID NOs: 96, 97; SEQ ID NOs: 98, 99; SEQ ID NOs: 100, 101; SEQ ID NOs: 102, 103; SEQ ID NOs: 104, 105; SEQ ID NOs: 106, 107; SEQ ID NOs: 108, 109; SEQ ID NOs: 110, 111; SEQ ID NOs: 112, 113; SEQ ID NOs: 114, 115; SEQ ID NOs: 116, 117; SEQ ID NOs: 118, 119; SEQ ID NOs: 193, 194 e) an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one amino acid sequence of d); and f) an amino acid sequence which has one or more (preferably one or several, more preferably one, two or three) amino acids which differ from at least one of the amino acid sequences of d).
[0019] In some embodiments, the antibodies of the invention have: a) the CH3-b of the fusion peptide and the CH3-a of the heavy chain have a pair of substitutions forming a protuberance-cavity structure, said substitutions including, for example, one or more of the substitutions in Table 15, for example, T366 in one CH3 domain is replaced by a relatively large amino acid residue, such as tyrosine (Y) or tryptophan (W), and Y407 in the other CH3 domain is replaced by a relatively small amino acid residue, such as threonine (T), alanine (A) or valine (V); b) the CH3-b of the fusion peptide and the CH3-a of the heavy chain have a substitution pair that forms an ionic bond, and the substitution includes, for example, one or more substitutions in Table 16, for example, one CH3 domain includes one or more substitutions of an amino acid residue that is positively charged under physiological conditions, and the other CH3 domain includes one or more substitutions of an amino acid residue that is negatively charged under physiological conditions, and the positively charged amino acid residue is, for example, arginine (R), histidine (H) or lysine (K), and the negatively charged amino acid residue may be, for example, aspartic acid (D) or glutamic acid (E), and the substituted amino acid residue is, for example, one or more of D356, L368, K392, D399 and K409; c) the CH3-b of the fusion peptide and the CH3-a of the heavy chain have a pair of substitutions that form a disulfide bond, the substitutions being, for example, those in Table 17; and / or d) the CH3-b of the fusion peptide and the CH3-a of the heavy chain have substitutions that result in a reduced ability to bind to Protein A, such as those in Table 18, for example, H435 and Y436 in one CH3 domain are replaced with arginine and phenylalanine, respectively.
[0020] In some embodiments, in the antibody of the present invention, the Fc fragment comprises a CH2 having any sequence selected from SEQ ID NO: 155-161 or 192, and / or a CH3 having any sequence selected from SEQ ID NO: 162-183.
[0021] In some embodiments, the heavy chain of the antibody of the invention or the heavy chain of the fusion peptide comprises a human Fc fragment or a humanized Fc fragment, such as a human IgG Fc fragment, such as an IgG1, IgG2, IgG3, IgG4, IgG5 Fc fragment.
[0022] In some embodiments, the heavy chain of an antibody of the invention, the heavy chain of a fusion peptide, and / or the Fc fragment of the fusion peptide comprises one or more substitutions compared to a wild-type antibody that form a protuberance-cavity pairing between the heavy chain and the fusion peptide.
[0023] In some embodiments, the heavy chain of the antibody of the invention and / or the Fc fragment of the fusion peptide comprises one or more substitutions that form salt bridge pairing between the heavy chain and the fusion peptide.
[0024] In some embodiments, the antibodies of the invention comprise Y101, Y102, Y103, Y104, Y105, Y150-8-3, Y150-F8-4, Y150-F8-5, Y150-F8-6, Y150-F8-7, Y150-F8-8, Y150-F8-9, Y150-F8-10, Y150-F8-11, Y150-F8-12, Y150-F8-13, Y150-F8-14, Y150-F8-15, Y150-F9-7, Y150-F9-11, Y150-F9-12, MS-hCD3-IC15, MS-hCD3-IC16, MS-hCD3-IC17, and MS-hCD3-IC18, Here, the components are arranged in the following order: fusion peptide VHs-linker1-VLs-hinge1-CH2-CH3-b, heavy chain VHm-CH1-hinge2-CH2-CH3-a, light chain VLm-CL. Y101 comprises SEQ ID NO: 45, 129, 63, 142, 159, 167, 106, 154, 139, 159, 166, 107, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of the amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of the amino acid sequences; Y102 comprises SEQ ID NO: 48, 129, 63, 142, 159, 167, 106, 154, 139, 159, 166, 107, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y103 comprises SEQ ID NO: 48, 129, 71, 142, 159, 167, 106, 154, 139, 159, 166, 107, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y104 comprises SEQ ID NO: 49, 129, 63, 142, 139, 167, 106, 154, 139, 159, 166, 107, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y105 comprises SEQ ID NO: 49, 129, 71, 142, 139, 167, 106, 154, 139, 159, 166, 107, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-8-3 comprises SEQ ID NOs: 45, 129, 63, 141, 157, 167, 90, 154, 139, 157, 166, 91, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-4 comprises SEQ ID NOs: 48, 129, 63, 141, 157, 167, 90, 154, 139, 157, 166, 91, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-5 comprises SEQ ID NOs: 49, 129, 71, 141, 139, 167, 90, 154, 139, 157, 166, 91, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-6 comprises SEQ ID NOs: 51, 129, 71, 141, 139, 167, 90, 154, 139, 157, 166, 91, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-7 comprises SEQ ID NOs: 49, 129, 71, 144, 158, 167, 90, 154, 139, 158, 166, 91, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-8 comprises SEQ ID NOs: 49, 129, 71, 144, 161, 167, 90, 154, 139, 161, 166, 91, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-9 comprises SEQ ID NOs: 49, 129, 71, 144, 161, 167, 96, 154, 139, 161, 166, 97, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-10 comprises SEQ ID NOs: 58, 129, 72, 144, 161, 167, 96, 154, 139, 161, 166, 97, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-11 comprises SEQ ID NOs: 60, 129, 72, 144, 161, 167, 96, 154, 139, 161, 166, 97, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-12 comprises SEQ ID NOs: 60, 129, 73, 144, 161, 167, 96, 154, 139, 161, 166, 97, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-13 comprises SEQ ID NOs: 59, 129, 72, 144, 161, 167, 96, 154, 139, 161, 166, 97, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-14 comprises SEQ ID NOs: 61, 129, 73, 144, 161, 167, 96, 154, 139, 161, 166, 97, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F8-15 comprises 62, 129, 73, 144, 161, 167, 96, 154, 139, 161, 166, 97, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F9-7 comprises 49, 129, 71, 141, 139, 167, 92, 154, 139, 157, 166, 93, 150, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F9-11 comprises 49, 129, 71, 144, 161, 167, 92, 154, 139, 161, 166, 93, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; Y150-F9-12 comprises 49, 129, 71, 144, 192, 167, 92, 154, 139, 192, 166, 93, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences; MS-hCD3-IC15 comprises 49, 129, 71, 141, 159, 167, 118, 154, 139, 159, 166, 119, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences, MS-hCD3-IC16 comprises 49, 129, 71, 141, 157, 167, 118, 154, 139, 157, 166, 119, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences, MS-hCD3-IC17 comprises 49, 129, 71, 141, 161, 167, 118, 154, 139, 161, 166, 119, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences, MS-hCD3-IC18 comprises 58, 129, 72, 141, 161, 167, 118, 154, 139, 161, 166, 119, 148, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with at least one of these amino acid sequences, or an amino acid sequence having one or more (preferably one or several, more preferably one, two or three) different amino acids from at least one of these amino acid sequences. In some embodiments, the present invention provides an antibody or antigen-binding fragment thereof, comprising: -8 M or less, for example, about 10 -8 M, 10 -9 M, 10 -10or binds to a target with an EC50 of about 100 nM or less, e.g., about 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM or less, and preferably said antigen-binding fragment is selected from F(ab')2, F(ab)2, Fab', Fab, Fv, Fd, scFv.
[0025] In some embodiments, the invention provides polynucleotides encoding the antibodies or antigen-binding fragments thereof described herein.
[0026] In some embodiments, the present invention provides an expression vector comprising a polynucleotide described herein.
[0027] In some embodiments, the invention provides a host cell comprising a polynucleotide or expression vector described herein.
[0028] In some embodiments, the invention provides a method for preparing an antibody of the invention, comprising introducing a polynucleotide or expression vector described herein into a host cell, thereby preparing said antibody.
[0029] In some embodiments, the present invention provides an antibody conjugate comprising an antibody or antigen-binding fragment thereof described herein and a conjugating moiety conjugated thereto, preferably selected from a purification tag (e.g., His tag), a cytotoxic agent, a detectable label, a radioisotope, a luminescent substance, a colored substance, an enzyme, or polyethylene glycol.
[0030] In some embodiments, the invention provides an antibody conjugate, wherein the antibody may be conjugated to a therapeutic agent, a prodrug entity, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a drug, or a macrogol.
[0031] In some embodiments, the antibody may be linked or fused to a therapeutic agent, which may include a detectable label such as a radiolabel, an immunomodulatory agent, a hormone, an enzyme, an oligonucleotide, a photoactive therapeutic or diagnostic agent, a cytotoxic agent (which may be a drug or a chemokine), an ultrasound enhancing agent, a non-radioactive label, combinations thereof, and other moieties of the same type known in the art.
[0032] In some embodiments, the antibody is detectably labeled by conjugation with a chemiluminescent compound, and the presence of the chemiluminescent-labeled antigen-binding polypeptide can be determined by detecting luminescence generated during the course of a chemical reaction. Particularly useful chemiluminescent labeling compounds include luminol, isoluminose, theromatic acridinium ester, imidazole, acridinium salt and oxalate.
[0033] In some embodiments, the antibody may also be detectably labeled with a fluorescent metal, such as 152Eu, or other lanthanide metals, which may be linked to the antibody with a metal chelating group, such as diethylene-triaminepentaacetic acid (DTPA), ethylenediaminetetraacetic acid (EDTA). Techniques for linking various groups to antibodies are known and include those described, for example, in Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy," in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. (1985); Hellstrom et al., "Antibodies For Drug Delivery," in Controlled Drug Delivery (2nd ed.), Robinson et al. (eds.), Marcel Dekker, Inc., pp. 623-53 (1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review," in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer See, for example, "Monoclonal Antibodies For Cancer Detection And Therapy," in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), Academic Press pp. 303-16 (1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates," Immunol. Rev. (52:119-58 (1982)).
[0034] In some embodiments, the invention provides a fusion protein comprising an antibody or antigen-binding fragment thereof described herein.
[0035] In some embodiments, the invention provides pharmaceutical compositions comprising an antibody or antigen-binding fragment thereof, antibody conjugate, or fusion protein described herein, and optionally further comprising a pharma- ceutically acceptable carrier and / or excipient.
[0036] In some embodiments, the pharmaceutical compositions described herein are in a form suitable for oral administration to the gastrointestinal (GI) tract, preferably, said dosage form is selected from tablets, capsules, pills, powders, granules, emulsions, microemulsions, solutions, suspensions, syrups and elixirs, or said pharmaceutical compositions are in a form suitable for subcutaneous, intradermal, intravenous, intramuscular or intralesional injection.
[0037] In some embodiments, the present invention provides a kit comprising an antibody or antigen-binding fragment thereof, antibody conjugate, or fusion protein described herein. Preferably, the kit further comprises a second antibody that specifically recognizes the antibody or antigen-binding fragment thereof, antibody conjugate, or fusion protein described herein. The second antibody optionally further comprises a detectable label, e.g., a radioisotope, a luminescent substance, a coloring substance, an enzyme.
[0038] In some embodiments, the invention provides said antibody or antigen-binding fragment thereof for the treatment of a disease, or provides the use of an antibody or antigen-binding fragment thereof described herein for the treatment of a disease, or the use of an antibody or antigen-binding fragment thereof described herein in the preparation of a medicament for the treatment of a disease.
[0039] In some embodiments, the antibodies described herein can be used in combination with other therapeutic agents (eg, therapeutic agents for treating tumors or cancer).
[0040] In some embodiments, the invention provides a kit comprising an antibody or antigen-binding fragment thereof described herein, a pharmaceutical carrier, instructions for use, and any other therapeutic agent (e.g., a therapeutic agent for treating a tumor or cancer).
[0041] In some embodiments, in the compositions and / or kits described herein, the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic moiety, an enzyme, a radioactive compound, a cytokine, an interferon, a target, or a reporting moiety.
[0042] In some embodiments, the antibodies or antigen-binding fragments thereof described herein can be used to treat a disease, such as a cancer or tumor.
[0043] In some embodiments, the invention provides the use of said antibody or antigen-binding fragment thereof for treating a disease, such as cancer or a tumor.
[0044] In some embodiments, the invention provides the use of an antibody or an antigen-binding fragment thereof for the preparation of a medicament for treating a disease, such as a cancer or a tumor.
[0045] In some embodiments, the antibodies or antigen-binding fragments thereof described herein can be used to treat diseases, such as cancer or tumors, including, but not limited to, multiple myeloma, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma).
[0046] In some embodiments, the present invention provides a method for humanizing an anti-CD3 antibody and the humanized sequence obtained therefrom, and the monoclonal and polyfunctional antibodies prepared based on the humanized antibody sequence have suitable affinity, high stability and good cell killing ability.
[0047] In some embodiments, the humanized anti-CD3 antibodies described herein exhibit superior biological activity and / or stability to other anti-CD3 antibodies in terms of biological activity and stability of multifunctional antibodies compared to control antibodies, such as the original antibody SP34, and anti-CD3 antibodies with high homology provided in other literature.
[0048] In some embodiments, the present invention provides a multifunctional antibody and a method for producing the antibody, the antibody comprising (a) a light chain-heavy chain pair and (b) a fusion peptide, the light chain-heavy chain pair having specificity for a tumor cell or a microorganism, the fusion peptide comprising a single chain variable region fragment (ScFv) and an Fc fragment having a CH2 domain and / or a CH3 domain, and the antibody having specificity for an immune cell.
[0049] In some embodiments, the light chain-heavy chain pair or VLm-VHm pairing of the antibody of the present invention has specificity for a tumor antigen. In some embodiments, the tumor antigen is selected from PD-L1, SLAMF7, CD38, BCMA, etc. In some embodiments, the light chain-heavy chain pair or VLm-VHm pairing has specificity for a protein that is overexpressed on tumor cells compared to corresponding non-tumor cells.
[0050] In some embodiments, the light chain-heavy chain pair or VLm-VHm pairing has specificity for a virus or bacteria. In one aspect, the light chain-heavy chain pair or VLm-VHm pairing has specificity for endotoxin.
[0051] In some embodiments, the immune cells are selected from T cells, CIK cells, NKT cells, B cells, monocytes, macrophages, neutrophils, dendritic cells, macrophages, natural killer cells, eosinophils, basophils, and mast cells.
[0052] In some embodiments, the ScFv or VLs-VHs pairing has specificity for an antigen, including, for example, CD3, CD4, CD8, CD40L, CD152, CD16, CD56, CD94, CD158, CD161, CD19, CD20, CD21, CD40. In some embodiments, the antigen is CD3.
[0053] In some embodiments, the light chain is linked to the heavy chain or fused heavy chain by a disulfide bond. In some embodiments, the heavy chain is linked to the fusion peptide by one or more disulfide bonds. In some embodiments, the fusion heavy chain 1 is linked to the fusion heavy chain 2 by one or more disulfide bonds. In some embodiments, the heavy chain or fused heavy chain comprises a human Fc fragment or a humanized Fc fragment. In some embodiments, the Fc fragment of the heavy chain or fused heavy chain comprises a human IgG Fc fragment. In some embodiments, the Fc fragment of the fusion peptide comprises a human Fc fragment or a humanized Fc fragment. In some embodiments, the Fc fragment of the fusion peptide comprises a human IgG Fc fragment.
[0054] In some cases, the heavy chain, fusion heavy chain and / or Fc fragment of the fusion peptide comprises one or more substitutions compared to a wild-type antibody fragment that form knobs-into-holes pairing between the heavy chain and the fusion peptide, which can significantly increase the pairing efficiency of the heavy chain-fusion peptide heterodimer.
[0055] In some cases, the heavy chain and / or the Fc fragment of the fusion peptide comprises one or more substitutions that form a salt-bridge between the heavy chain and the fusion peptide, which can significantly improve the pairing efficiency of the heterodimer of the heavy chain and the fusion peptide.
[0056] In some cases, the CH2 domain of the fusion peptide is located between the scFv fragment and the CH3 domain. In one embodiment, the fusion peptide does not include a CH1 domain.
[0057] In one embodiment, the invention further provides a composition comprising the antibody of any of the previous embodiments, hi one aspect, the carrier is a pharmaceutical carrier.
[0058] In another embodiment, the invention provides a conjugate comprising the antibody of any of the above embodiments that binds to one or more antigens. [Brief description of the drawings]
[0059] [Figure 1] Figure 1A shows a schematic diagram of an antibody structure, and Figure 1B shows a schematic diagram of the primary protein structure of each component of an antibody. [Diagram 2] FIG. 2 shows a schematic diagram of the primary protein structure of each component of a monoclonal antibody. [Diagram 3] FIG. 3 shows the expression level of humanized CD3 monoclonal antibody. [Figure 4] FIG. 4 shows the binding ability of monoclonal antibodies to CD3+ T cells. [Diagram 5] FIG. 5 shows the expression levels of multifunctional antibodies assembled with humanized anti-CD3 antibodies after transient transfection into CHO cells. [Figure 6] FIG. 6 shows the affinity of existing anti-CD3 monoclonal antibodies to cells. [Figure 7] FIG. 7 shows the in vitro activation ability of various multifunctional antibodies of the present invention on T cells. [Figure 8] FIG. 8 shows the in vitro killing ability of various multifunctional antibodies against multiple myeloma cells MC / CAR. [Figure 9] FIG. 9 shows the in vitro killing ability of various multifunctional antibodies against lung cancer cells H358. [Figure 10]FIG. 10 shows accelerated thermal stability test at 40° C. in a citrate buffer system for the multifunctional antibody Y105 of the present invention, and comparative antibodies Y106, CT-F4, CT-F5, and CT-F6. [Figure 11] FIG. 11 shows accelerated thermal stability tests at 40°C in a citrate buffer system for the multifunctional antibodies Y150-F8-5, Y150-F8-6, Y150-F8-7, and Y150-F8-8 of the present invention and comparative antibodies Y150-F8-1, Y150-F8-2, CT-F1, CT-F2, and CT-F3. [Figure 12] FIG. 12 shows accelerated thermal stability tests at 40°C in a citrate buffer system for the multifunctional antibodies Y150-F8-9, F8-10, F8-12, F9-7, and F9-11 of the present invention and comparative antibodies Y150-F8-1, Y150-F9-6, CT-F1, CT-F2, and CT-F3. [Figure 13] FIG. 13 shows accelerated thermal stability tests at 40° C. in a citrate buffer system for the multifunctional antibodies MS-hCD3-IC15, IC16, IC17, and IC18 of the present invention and comparative antibodies IC-2 to IC-7. [Figure 14] FIG. 14 shows accelerated thermal stability test at 40°C in a histidine buffer system for the multifunctional antibodies Y150-F8-5, Y150-F8-6, Y150-F8-7, and Y150-F8-8 of the present invention and comparative antibodies Y150-F8-1, Y150-F8-2, CT-F1, CT-F2, and CT-F3. [Figure 15] FIG. 15 shows accelerated thermal stability tests at 40°C in a histidine buffer system for the multifunctional antibodies Y150-F8-9, F8-10, F8-12, F9-7, and F9-11 of the present invention and comparative antibodies Y150-F8-1, Y150-F9-6, CT-F1, CT-F2, and CT-F3. [Figure 16] FIG. 16 shows accelerated thermal stability tests at 40° C. in a histidine buffer system for the multifunctional antibodies MS-hCD3-IC15, IC16, IC17, and IC18 of the present invention and comparative antibodies IC-2 to IC-7. [Figure 17] FIG. 17 shows the acid resistance stability test in a citrate buffer system at pH 3.5 for the multifunctional antibody Y105 of the present invention, and the comparative antibodies Y106, CT-F4, CT-F5, and CT-F6. [Figure 18] FIG. 18 shows an acid resistance stability test in a citrate buffer system at pH 3.5 for the multifunctional antibodies of the present invention Y150-F8-5, Y150-F8-6, Y150-F8-7, and Y150-F8-8, and comparative antibodies Y150-F8-1, Y150-F8-2, CT-F1, CT-F2, and CT-F3. [Figure 19] FIG. 19 shows an acid resistance stability test in a citrate buffer system at pH 3.5 for the multifunctional antibodies of the present invention Y150-F8-9, F8-10, F8-12, F9-7, and F9-11, and comparative antibodies Y150-F8-1, Y150-F9-6, CT-F1, CT-F2, and CT-F3. [Figure 20] FIG. 20 shows the acid resistance test in a citrate buffer system at pH 3.5 for the multifunctional antibodies MS-hCD3-IC15, IC16, IC17 and IC18 of the present invention and comparative antibodies IC-2 to IC-7. [Figure 21] Figure 21 shows the in vivo effect of various multifunctional antibodies in mouse tumor model and tumor volume monitoring. Here, Figure 21A shows the multifunctional antibody Y150-F8-8 of the present invention, Figure 21B shows the multifunctional antibody F8-9 of the present invention, and Figure 21C shows the multifunctional antibody F9-11 of the present invention. The sequences of anti-CD3 antibodies are all VH2a and VL5, and the sequences of anti-CD38 antibodies are different from each other. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0060] definition A naturally occurring antibody contains six "complementarity determining regions" or "CDRs" that are specifically positioned to form an antigen-binding domain. The remaining amino acids of the antigen-binding domain are called "framework" regions and have fewer intramolecular variabilities. The framework regions are primarily β-folded sheet conformation, while the CDRs form loops that connect to and may become part of the β-folded sheet conformation. Thus, the framework regions form a scaffold that orients the CDRs by intrachain non-covalent interactions. The antigen-binding domain formed by the positioned CDRs defines a surface that is complementary to the immunoreactive antigen epitope. The complementary surface contributes to the non-covalent binding of the antibody to its homologous epitope. One of skill in the art can readily recognize any given heavy or light chain variable region from the amino acids which comprise the CDRs and framework regions, respectively (see, "Sequences of Proteins of Immunological Interest," Kabat, E., et al., USDepartment of Health And Human Services, (1983); Chothia and Lesk, J. MoI. Biol., 196:901-917 (1987)).
[0061] As used herein, the term "complementarity determining region" ("CDR") refers to the non-contiguous antigen-binding sites present in the variable regions of both heavy and light chain polypeptides. Such specific regions are described by Kabat et al., U.S. Department of Health and Public Service, "Sequences of Proteins of Immunological Interest" (1983), and by Chothia et al., J. MoI. Biol. 196:901-917 (1987). As defined by Kabat and Chothia, CDRs include overlapping amino acid residues or amino acid substructures when compared to each other. However, all applications of the definition to CDRs of an antibody or variants thereof are within the scope of the term as defined and used herein. Given the variable region amino acid sequence of the antibody, one of skill in the art can generally determine which residues comprise a particular CDR.
[0062] Kabat et al. also defined a numbering system for variable domain sequences that is applicable to any antibody. The "Kabat numbering" system can be used by those skilled in the art for any variable domain sequence without any doubt and without reliance on any experimental data other than the sequence itself. As used herein, "Kabat numbering" refers to the numbering system described by Kabat et al., the contents of which are set forth in the U.S. Department of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).
[0063] The CDR regions, as described by the Kabat numbering system, are as follows: CDR-H1 begins at about the 31st amino acid (i.e., about 9 residues from the first cysteine residue) and ends at the next tryptophan residue, and includes about 5-7 amino acids. CDR-H2 begins at the 15th residue after the end of CDR-H1 and ends at the next arginine or lysine residue, and includes about 16-19 amino acids. CDR-H3 begins at about the 33rd amino acid after the end of CDR-H2 and includes 3-25 amino acids and ends at the sequence WGXG, where X is any amino acid. CDR-L1 begins at about the 24th residue (i.e., after the cysteine residue) and ends at the next tryptophan residue, and includes about 10-17 residues. CDR-L2 begins at about the 16th residue after the end of CDR-L1 and includes about 7 residues. CDR-L3 begins approximately 33 residues after the end of CDR-L2 (i.e., after the cysteine residue) and includes about 7-11 residues, ending with the sequence F or WGXG, where X is any amino acid.
[0064] The antibodies described herein may be from any animal, including birds and mammals, including primates. Preferably, the antibodies are human, baboon, rhesus, cynomolgus, murine, donkey, rabbit, goat, guinea pig, camel, alpaca, horse or chicken.
[0065] The humanized antibodies described herein can specifically bind to CD3, eg, primate CD3, including, for example, human and / or monkey CD3.
[0066] The term "heavy chain constant region" as used herein includes an amino acid sequence derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain constant region includes at least a CH1 domain, a hinge (e.g., an upper hinge region, a middle hinge region, and / or a lower hinge region), a CH2 domain, a CH3 domain, or any variant or fragment thereof. For example, an antigen-binding polypeptide for use in the present invention may include a polypeptide chain having a CH1 domain; a polypeptide having a CH1 domain, at least a portion of a hinge domain, and a CH2 domain; a polypeptide chain having a CH1 domain and a CH3 domain; a polypeptide chain having a CH1 domain, at least a portion of a hinge domain, and a CH3 domain, or a polypeptide chain having a CH1 domain, at least a portion of a hinge domain, a CH2 domain, and a CH3 domain. In another embodiment, a polypeptide of the present invention includes a polypeptide chain having a CH3 domain. An antibody of the present invention may also lack at least a portion of a CH2 domain (e.g., all or a portion of a CH2 domain). It should be understood by one of ordinary skill in the art that the heavy chain constant region may be altered so that it differs in amino acid sequence from that of a naturally occurring immunoglobulin molecule.
[0067] The heavy chain constant regions of the antibodies described herein may be derived from different immunoglobulin molecules. For example, the heavy chain constant region of the polypeptide may comprise a CH1 domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule. In another form, the heavy chain constant region may comprise a hinge region that is partially derived from an IgG1 molecule and partially derived from an IgG3 molecule. In another form, the heavy chain portion may comprise a chimeric hinge that is partially derived from an IgG1 molecule and partially derived from an IgG4 molecule.
[0068] As used herein, the term "light chain constant region" includes an amino acid sequence derived from an antibody light chain. Preferably, the light chain constant region includes at least one of a kappa constant domain and a lambda constant domain.
[0069] A "light chain-heavy chain pair" refers to an assembly of a light chain and a heavy chain that can form a dimer via disulfide bonds between the CL and CH1 domains of the light chain.
[0070] The subunit and three-dimensional structures of the constant regions of the various immunoglobulin classes are known. The term "VH domain" comprises the amino-terminal variable domain of an immunoglobulin heavy chain. The term "CH1 domain" comprises the first (often amino-terminal) constant region of an immunoglobulin heavy chain. The CH1 domain is adjacent to the VH domain and is amino-terminal to the hinge region of the immunoglobulin heavy chain molecule.
[0071] The term "CH2 domain" as used herein includes a portion of a heavy chain molecule, for example, ranging from about residue 244 to residue 360 of an antibody in the common numbering scheme (corresponding to residues 244 to 360 in the Kabat numbering system and residues 231-340 in the EU numbering system, see Kabat et al., U.S. Department of Health and Public Service, "Sequences of Proteins of Immunological Interest" (1983)). The CH2 domain is unique in that it is not tightly paired with the other domain. Instead, both N-linked side chain carbohydrate chains are inserted between both CH2 domains in intact native IgG molecules. The literature describes the CH3 domain as extending from the CH2 domain to the C-terminus of the IgG molecule and containing about 108 residues.
[0072] As used herein, the term "hinge region" includes the portion of the heavy chain molecule that connects the CH1 domain to the CH2 domain. The hinge region contains approximately 25 residues and is flexible, allowing both N-terminal antigen-binding regions to move independently. The hinge region can be divided into three distinct domains: the upper, middle, and lower hinge domains (Roux et al., J. Immunol, 161:4083 (1998)).
[0073] The term "disulfide bond" as used herein includes a covalent bond formed between two sulfur atoms. The amino acid cysteine contains a sulfhydryl group that can form or bridge a disulfide bond with another sulfhydryl group. In most naturally occurring IgG molecules, the CH1 and CL regions are linked by a disulfide bond, and both heavy chains are linked by two disulfide bonds corresponding to positions 239 and 242 in the Kabat numbering system (positions 226 and 229 in the EU numbering system).
[0074] As used herein, the term "chimeric antibody" refers to an antibody in which the immune reactive region or site is from or obtainable from a first species and the constant region (which may be complete, partial or modified according to the present invention) is from a second species. In some embodiments, the target binding region or site is of non-human (e.g., murine or primate) origin and the constant region is of human origin.
[0075] As used herein, the "humanized percentile" is calculated by determining the number of in-frame amino acid differences (i.e., non-CDR differences) between the humanized domain and its species domain, subtracting that number from the total number of amino acids, dividing by the total number of amino acids and multiplying by 100.
[0076] The term "specifically binds" or "has specificity for" generally means that an antibody binds to an antigen epitope through its antigen-binding domain, and that this binding necessarily has a certain complementarity between the antigen-binding domain and the antigen epitope. By this definition, an antibody is considered to "specifically bind" to an antigen epitope if the antibody binds to the antigen epitope more readily through its antigen-binding domain than to a random, unrelated antigen epitope. As used herein, the term "specificity" is used to determine the affinity with which an antibody binds to a particular antigen epitope. For example, antibody "A" may be considered to have a higher specificity for a particular antigen epitope than antibody "B". Or, antibody "A" may be said to have a higher specificity for binding to correlated antigen epitope "D" compared to antigen epitope "C". In some embodiments, the antibodies of the present invention have a specificity of about 10 -8 Less than M, e.g., about 10 -8 M, 10 -9 M, 10 -10 In some embodiments, the antibodies of the invention bind to a target with an EC50 of less than about 100 nM, e.g., less than about 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM or less.
[0077] In addition, when there is no clear limit to the number, an entity is understood to refer to one or more (species) of the entity. For example, a "multifunctional antibody" is understood to refer to one or more (species) of multifunctional antibodies. Similarly, when there is no clear limit to the number, the terms "one or more" and "at least one" can be used interchangeably herein.
[0078] The term "polypeptide" as used herein includes the singular "polypeptide" as well as the plural "polypeptides" and refers to a molecule consisting of monomers (amino acids) linearly linked through amide bonds (also called peptide bonds). The term "polypeptide" refers to a chain or chains of amino acids or amino acids, and does not refer to a specific length. Thus, peptide, dipeptide, terpeptide, oligopeptide, "protein", "chain of amino acids", or other terms referring to any chain or chains of amino acids or amino acids are all included in the definition of "polypeptide". The term "polypeptide" may also be used in place of or interchangeably with these terms. The term "polypeptide" refers to the product of post-expression modifications of a polypeptide, including, but not limited to, glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, hydrolytic dissolution of proteins, or modifications of non-naturally occurring amino acids. A polypeptide may be derived from a naturally occurring organism or produced by homologous recombination techniques, but is not necessarily translated from a specified nucleic acid sequence. They can be made in any manner, including chemical synthesis.
[0079] As used herein, the term "isolated" with respect to cells, nucleic acids (e.g., DNA or RNA) refers to molecules that are isolated from DNA or RNA, respectively, that are present as other naturally occurring larger molecules. As used herein, the term "isolated" also refers to nucleic acids or peptides that are substantially free of cellular material, viral material, or culture medium, when produced by recombinant DNA techniques, or substantially free of chemical precursors or other chemicals, when produced by chemical synthesis. "Isolated nucleic acid" also refers to nucleic acid fragments that are not found in the natural state, including non-naturally occurring fragments. As used herein, the term "isolated" also refers to cellular proteins or tissues, cells, or polypeptides that are isolated. Isolated polypeptides include purified or recombinant polypeptides.
[0080] As used herein, the term "recombinant" when referring to a polypeptide or polynucleotide refers to a form of a polypeptide or polynucleotide that does not exist in the natural state, where one non-limiting example can be achieved by combining polynucleotides, or polypeptides, that do not normally exist together.
[0081] "Homology" or "identity" or "similarity" refers to the degree of sequence similarity between two peptide chain molecules or between two nucleic acid molecules. Homology can be measured by comparing the positions of each sequence. Comparison can be performed by alignment. If the same base or amino acid is present at a certain position in the compared sequences, the molecules at that position are considered to be homologous. The degree of homology between multiple sequences is a function of the number of pairings or homologous sites shared by the sequences. An "unrelated" or "non-homologous" sequence has less than 40% homology with one of the sequences of the present invention, preferably less than 25% homology.
[0082] A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) having a "sequence identity" with another sequence at a certain percentile (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) means that the two sequences, when aligned, have similar bases (or amino acids) at that percentile when compared. Such alignment, percentile homology or sequence identity can be measured by software programs known in the art, such as those described in Current Protocols in Molecular Biology, edited by Ausubel et al. (2007). Preferably, default parameters are used for alignment. Biologically equivalent polynucleotides refer to polynucleotides that have the specific percentile homology as described above, while at the same time encoding the same or similar biologically active polypeptides.
[0083] The term "equivalent nucleic acid or polynucleotide" refers to a nucleic acid whose nucleotide sequence has a predetermined degree of homology or sequence identity with the nucleotide sequence of the nucleic acid or its complementary sequence. A double-stranded nucleic acid homolog refers to a nucleic acid that contains a particular nucleotide sequence that has a predetermined degree of homology with another nucleic acid or its complementary sequence. In one embodiment, a homolog / homolog of a nucleic acid is one that can hybridize with the nucleic acid or its complementary sequence. Similarly, an "equivalent polypeptide" refers to a polypeptide that has a predetermined degree of homology or sequence identity with the amino acid sequence of a reference polypeptide. In some cases, the sequence identity is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%. In some cases, the equivalent sequence retains the activity (e.g., ability to bind to an antigenic epitope) or structure (e.g., salt bridges) of the reference sequence.
[0084] Hybridization reactions may be performed under different "stringent" conditions. Generally, low stringency hybridization reactions are performed at about 40° C. in about 10×SSC or a solution of equivalent ionic strength / temperature. Medium stringency hybridization reactions are generally performed at about 50° C. in about 6×SSC, and high stringency hybridization reactions are generally performed at about 60° C. in about 1×SSC. Hybridization reactions may be performed under "physiological conditions" as is well known to those skilled in the art. Non-limiting examples of physiological conditions include temperature, ionic strength, pH value, and Mg2+ concentration that are normal in cells.
[0085] A polynucleotide is composed of a specific sequence of four nucleotide bases: adenine (A), cytosine (C), guanine (G) and thymine (T). If the polynucleotide is RNA, thymine is replaced by uracil (U). The term "polynucleotide sequence" is therefore an ordered letter representation of a polynucleotide molecule. The ordered letter representation can be entered into a database for use in bioinformatics applications, such as functional genomics and homology searches, on a computer with a central processing unit. The term "polymorphism" refers to the coexistence of one or more genes or parts thereof. If a part of a gene has at least two different types, i.e., two different nucleotide sequences, then that part of the gene is called a "polymorphic region of a gene". A polymorphic region may be a mononucleotide with different identities for different alleles.
[0086] The terms "polynucleotide" and "oligonucleotide" are used interchangeably and refer to a polymeric form of nucleotides of any length. The polymeric form of nucleotides may be deoxyribose nucleotides, ribose nucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure and may have any known or unknown function. Non-limiting examples of polynucleotides include genes or gene fragments (e.g., probes, primers, EST or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, dsRNA, siRNA, miRNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, DNA of any single sequence, RNA of any single sequence, nucleic acid probes, and primers. Polynucleotides may contain modified nucleotides, such as methylated nucleotides or nucleotide analogs. When modified nucleotides are present, the base structure is modified before or after assembly of the polynucleotide. The nucleotide sequence may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, for example, by attachment of a labeling component. The term also refers to double-stranded and single-stranded molecules. Each embodiment of the polynucleotide of the present invention includes the double-stranded form, the two complementary single-stranded forms that are known, and those that are expected to be in double-stranded form, unless otherwise indicated or claimed.
[0087] The term "encode" when applied to a polynucleotide refers to a polynucleotide that is believed to "code" a particular polypeptide. When the polynucleotide is in its natural state or manipulated by methods known to those of skill in the art, it can be transcriptome and / or translated to produce the mRNA of the polypeptide and / or fragments thereof. The antisense strand is the complement of such a nucleic acid. The coding sequence can be derived from the antisense strand.
[0088] The term "detectable tag" as used herein refers to a compound or composition that can be directly or indirectly detected. The compound or composition can be directly or indirectly bound to a composition to be detected (e.g., a polynucleotide or a protein, including an antibody) to obtain a "tagged" composition. The term also refers to a sequence that binds to the polynucleotide that provides a signal, such as green fluorescent protein (GFP), upon expression of the inserted sequence. The tag can be detectable by itself (e.g., a radioisotope tag, a fluorescent tag) or an enzymatic tag that can catalyze a detectable chemical change in a substrate compound or composition. The tag can be used for small scale assays, but is more suitable for high flux screening. Similarly, suitable tags include, but are not limited to, radioisotopes, fluorescent dyes, chemiluminescent compounds, dyes, and proteins (including enzymes). The tag can be detectable only, or can be quantified. A detectable only reaction typically includes a reaction whose presence can only be confirmed. As used herein, a quantifiable response typically includes a response that has a quantifiable (e.g., numerically reportable) value of intensity, polarization, and / or other property. In luminescence or fluorescence assays, the detectable response may be direct, using a luminophore or fluorescent group that is actually associated with the binding of the analytical component, or indirect, using a luminophore or fluorescent group that is linked to another component (e.g., a reporter molecule or indicator).
[0089] As used herein, an "antibody" or "antigen-binding polypeptide" refers to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen. An antibody may be a whole antibody or any antigen-binding fragment or single chain thereof. Thus, the term "antibody" includes any protein or peptide containing a specific molecule that includes at least a portion of an immunoglobulin molecule that has biological activity of binding to an antigen. Examples of such embodiments include, but are not limited to, at least a portion of the complementarity determining regions (CDRs) of a heavy or light chain or a ligand binding portion thereof, the variable region of a heavy or light chain, the constant region of a heavy or light chain, the framework (FR) region or any portion thereof, or a binding protein.
[0090] The term "antibody fragment" or "antigen-binding fragment" as used herein refers to a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc. Antibody fragments that bind to the same antigen, regardless of structure, are considered to be intact antibodies. The term "antibody fragment" includes aptamers, aptamer enantiomers, and dimers. The term "antibody fragment" also includes synthetic or genetically engineered proteins that, like antibodies, are capable of binding to a specific antigen to form a complex.
[0091] "Single chain variable region fragment" or "scFv" refers to a fusion protein of the variable regions of the heavy (VH) and light (VL) chains of an immunoglobulin. In some cases, these regions are linked by a short linker peptide of 10 to about 25 amino acids. The linker may be glycine-rich for flexibility or may contain serine or threonine for solubility. The N-terminus of VH may be linked to the C-terminus of VL, or vice versa. The protein retains the properties of the original immunoglobulin, with only the constant regions removed and the linker introduced. ScFv molecules are known in the art and include those described in U.S. Pat. No. 5,892,019.
[0092] As will be appreciated by those skilled in the art, heavy chains are divided into gamma, mu, alpha, delta, and epsilon (γ, μ, α, δ, ε) with several subclasses (e.g., γ1-4). The "class" of an antibody, e.g., IgG, IgM, IgA, IgG, or IgE, is determined by the properties of the chain. Immunoglobulin subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgG5, etc., are well characterized and functionally specific. With reference to this specification, the skilled artisan can readily identify all modified forms of these classes and isotypes, and these forms are therefore within the scope of the present invention. All immunoglobulin classes are expressly within the scope of this application, and the following description is generally directed to the IgG class of immunoglobulin molecules. IgG is a standard immunoglobulin molecule that contains two identical light polypeptide chains (each with a molecular weight of about 23,000 daltons) and two identical heavy polypeptide chains (each with a molecular weight of 53,000-70,000). These four chains are typically joined by disulfide bonds in a "Y" configuration, where the light chains support the heavy chains at the mouth of the "Y" and extend beyond the variable region.
[0093] Antibodies, antigen-binding polypeptides, variants or derivatives thereof of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized, primatized or chimeric antibodies, single chain antibodies, antigen epitope-binding fragments, such as Fab, Fab' and F(ab')2, Fd, Fv, single chain Fv (scFv), single chain antibodies, disulfide-linked Fv (sdFv), fragments comprising a VL domain or a VH domain, fragments generated by a Fab expression library, and anti-idiotypic (anti-Id) antibodies (including, for example, the anti-Id antibodies or LIGHT antibodies disclosed herein). Immunoglobulin or antibody molecules of the present invention may be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule.
[0094] Light chains are classified as kappa or lambda (κ, λ). Each class of heavy chain can be bound to either kappa or lambda light chains. Light chains are always covalently bound to heavy chains. Furthermore, when these immunoglobulins are produced by hybridomas, B cells or genetically engineered host cells, the "tail" portions of the two heavy chains are bound by covalent disulfide bonds or non-covalent bonds. In the heavy chains, the amino acid sequence extends from the N-terminus of the fork of the Y-shaped structure to the bottom C-terminus of each chain.
[0095] Both light and heavy chains are divided into structural and functional homologue regions. The terms "constant" and "variable" are used for functional purposes. It should be recognized here that the light chain variable domain (VL) together with the heavy chain variable domain (VH) determine antigen recognition and specificity. On the other hand, the light chain constant domain (CL) and the heavy chain constant domain (CH1, CH2 or CH3) provide important biological properties such as secretion, mobility across the placenta, binding to Fc receptors, binding to complement, etc. In general, the number of constant region domains increases with distance from the antigen binding site or amino-terminal position of the antibody. The N-terminal portion is the variable region, the C-terminal portion is the constant region, and the CH3 and CL domains actually comprise the carboxy termini of the heavy and light chains, respectively.
[0096] As described above, the variable region allows the antibody to selectively recognize and specifically bind to an antigenic epitope of an antigen. That is, the VL domain and VH domain of an antibody, or a subclass of complementarity determining region (CDR), combine to form a variable region that defines a three-dimensional antigen-binding site. The tetravalent antibody structure forms an antigen-binding site. The antigen-binding site is present at the end of each arm of the Y-shape. More specifically, the antigen-binding site is defined by three CDRs of each VH and VL chain (i.e., CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3). In some instances, for example, immunoglobulins derived from a certain species or modified based on immunoglobulins, the complete immunoglobulin molecule may be composed of only heavy chains and may not include light chains. See, for example, Hamers-Casterman et al., Nature 363:446-448 (1993).
[0097] As used herein, the term "treatment" refers to therapeutic treatment and prophylaxis, or prophylactic and curative measures to prevent or slow (alleviate) an undesirable physiological change or progression of a disease, such as cancer, in a subject. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, whether detectable or not, reduction in the stage of a disease, stabilization of a disease state (e.g., preventing it from getting worse), delay or slowing of disease progression, improvement or palliation of a disease state, and remission (whether partial or total). "Treatment" may also refer to a prolongation of survival compared to expected survival in the absence of treatment. Conditions requiring treatment include those already suffering from a disease or condition, those predisposed to a disease or condition, or those for preventing a disease or condition.
[0098] As used herein, the terms "subject," "individual," "animal," "patient," or "mammal" refer to any subject in need of diagnosis, prognosis, or treatment, particularly a mammalian subject. Mammalian subjects include humans, domesticated animals, farm animals, zoo, exercise, or pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, rats, horses, cows, dairy cows, and primates (e.g., humans, monkeys such as cynomolgus monkeys and rhesus monkeys, baboons, chimpanzees, etc.).
[0099] As used herein, the terms, e.g., "patient in need of treatment" or "subject in need of treatment", include mammalian subjects, e.g., humans, who will benefit from the administration of the antibodies and compositions of the invention, e.g., testing, diagnostic procedures and / or treatments.
[0100] multifunctional antibody One embodiment of the present invention provides heterodimeric antibodies that are composed of two different antigen-binding polypeptide units. In some cases, the heterodimer differs in size from its corresponding homodimer. This size difference can be exploited to aid in the separation of the heterodimer and homodimer.
[0101] In some cases, as in Figure 1, one of the two antigen-binding polypeptide units comprises a light-heavy chain pair resembling a wild-type antibody. Throughout this specification, such units are also referred to as "monovalent units."
[0102] In some cases, as shown in Figure 1, the other antigen-binding polypeptide unit comprises a single chain variable region fragment (scFv). The scFv can be fused to the N-terminus of the constant fragment (Fc) of an antibody and is called a fusion peptide. Throughout this specification, this fusion peptide is also referred to as a "single chain unit."
[0103] The present invention provides a multifunctional antibody and a method for producing the same, which comprises (a) a light-heavy chain pair specific for tumor cells, and (b) a fusion peptide specific for immune cells, comprising a single-chain variable fragment (ScFv) and an Fc fragment having a CH2 domain and / or a CH3 domain. The antibody is called a multifunctional antibody.
[0104] Any of the above antibodies or polypeptides may also comprise additional polypeptides, such as those described herein, a signal peptide of an antibody constant region to direct secretion, or other heterologous polypeptides as described herein.
[0105] As will be appreciated by those of ordinary skill in the art, antibodies derived from naturally occurring binding polypeptides described herein may be modified to have different amino acid sequences from these naturally occurring binding polypeptides. For example, a polypeptide or amino acid sequence derived from a particular protein may be similar to the starting sequence, e.g., have a certain percentage of identity with the starting sequence. For example, it may have 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity with the starting sequence.
[0106] Nucleotide or amino acid substitutions, deletions, or insertions may also be made to make conservative substitutions or changes to "non-essential" amino acid regions. For example, a polypeptide or amino acid sequence derived from a particular protein can be identical to a starting sequence except for one or more independent amino acid substitutions, insertions, or deletions, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more independent amino acid substitutions, insertions, or deletions. In some embodiments, a polypeptide or amino acid sequence derived from a particular protein has 1-5, 1-10, 1-15, or 1-20 independent amino acid substitutions, insertions, or deletions from the starting sequence.
[0107] In some embodiments, the antigen-binding polypeptide comprises an amino acid sequence or one or more groups that are not typically associated with an antibody. Exemplary modifications are described in more detail below. For example, the single-chain Fv antibody fragments of the invention may comprise a flexible linker sequence or may be modified to attach a functional group (e.g., polyethylene glycol (PEG), a drug, a toxin, or a label).
[0108] The antibodies, variants or derivatives of the present invention include modified derivatives, i.e., any type of molecule may be covalently linked to the antibody, and the covalent linkage does not prevent the antibody from binding to the antigen epitope. For example, but not limited to, the antibodies may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / cleaving groups, proteolytic lysis, linkage to cellular ligands or other proteins, etc. Any of a number of chemical modifications may be performed by known techniques, including, but not limited to, specific chemical lysis, acetylation, formylation, tunicamycin metabolism synthesis, etc. Additionally, the antibodies may contain one or more non-classical amino acids.
[0109] In other embodiments, the antigen-binding polypeptides of the invention may contain conservative amino acid substitutions.
[0110] A "conservative amino acid substitution" is a substitution of an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains are defined in the art and include basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, threonine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, it is preferred that non-essential amino acid residues in immunoglobulin polypeptides are replaced with other amino acid residues from the same side chain family. In another embodiment, consecutive amino acids can be replaced with structurally similar consecutive amino acids that differ in order and / or side chain family composition.
[0111] Methods for producing antibodies Methods for producing antibodies are known in the art and are described herein. In some embodiments, the variable and constant regions of the antigen-binding polypeptides of the invention are fully human. Fully human antibodies can be prepared by techniques described in the prior art and as described herein. For example, fully human antibodies against a particular antigen can be prepared by administering that antigen to a genetically modified animal whose endogenous locus has been inhibited and which has been engineered to produce antibodies in response to this type of antigenic challenge. Exemplary techniques by which such antibodies can be produced are described in U.S. Patents: 6,150,584, 6,458,592, and 6,420,140, which are incorporated herein by reference in their entireties.
[0112] In some embodiments, the antibodies prepared do not elicit an adverse immune response in the treated animal (e.g., human). In one embodiment, the antigen-binding polypeptides of the invention, variants or derivatives thereof are modified by techniques known in the art to reduce their immunogenicity. For example, the antibodies can be humanized, primatized, deimmunized, or chimerized. These types of antibodies are derived from non-human antibodies, usually murine or primate antibodies. The antibodies retain or largely retain the antigen-binding properties of the parent antibody, but are less immunogenic in the human body. This can be achieved in several ways, including (a) grafting the entire non-human variable domain onto a human constant region to create a chimeric antibody, (b) grafting at least a portion of one or more non-human complementarity determining regions (CDRs) onto human framework and constant regions, optionally retaining critical framework residues, or (c) grafting the entire non-human variable domain, but "covering" it with a human-like portion by replacing surface residues.
[0113] Deimmunization can be used to reduce the immunogenicity of an antibody. As used herein, the term "deimmunization" includes modifying an antibody to change its T cell antigen epitopes (see, for example, International Patent Publication Nos. WO / 9852976 A1 and WO / 0034317 A2). For example, the present application analyzes the variable heavy and variable light chain sequences from a starting antibody to generate a "map" of human T cell antigen epitopes from each V region. The map indicates the location of antigen epitopes relative to the complementarity determining regions (CDRs) and other important residues in the sequence. From the T cell antigen epitope map, single T cell epitopes can be analyzed to identify alternative amino acid substitutions with low risk of altering the activity of the final antibody. The present application designs a set of selectable variable heavy and light chain sequences, including combinations of amino acid substitutions, which are then incorporated into a set of binding polypeptides. Typically, 12-24 antibodies are generated and tested for binding and / or functionality. Then, the complete heavy and light chain genes containing the modified variable regions and human constant regions are cloned into expression vectors and the resulting plasmids are introduced into cell lines to produce whole antibodies. These antibodies are then compared by appropriate biochemical and biological assays to identify the best variants.
[0114] The binding specificity of an antigen-binding polypeptide of the invention can be determined, for example, by in vitro experiments such as immunoprecipitation, radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).
[0115] The single chain units of the present invention can be prepared using techniques for preparing single chain units described in (U.S. Pat. No. 4,694,778; Bird, Science 242:423-442 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 55:5879-5883 (1988); Ward et al., Nature 334:544-554 (1989)). Single chain fusion peptides can be obtained by linking the heavy and light chain fragments of the Fv region via an amino acid bridge to form a single chain unit. Techniques for synthesizing functional Fv fragments in E. coli (Skerra et al., Science 242:1038-1041 (1988)) can also be used.
[0116] Examples of techniques used to produce single chain Fvs (scFvs) and antibodies include those described in U.S. Patent Nos. 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., Proc. Natl. Sci. USA 90:1995-1999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For certain applications, including the use of antibodies in humans and in vitro assays, chimeric, humanized or human antibodies are preferred. Chimeric antibodies are molecules in which different portions of the antibody are derived from different animal species, e.g., antibodies that contain a variable region from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See, e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., J. Immunol. Methods 125:191-202 (1989); U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, each of which is incorporated by reference in its entirety.
[0117] A humanized antibody is an antibody molecule derived from a non-human species that binds to a desired antigen, the antibody molecule having one or more complementarity determining regions (CDRs) derived from the non-human species and a framework region derived from a human immunoglobulin molecule. In general, frame residues in the human framework regions are modified by substitution of corresponding residues from the CDR donor antibody, preferably to increase antigen binding capacity. These frame substitutions can be recognized by methods known in the art. For example, by establishing an interaction model of the CDR and frame residues, the frame residues that are relatively important for antigen binding and sequence are identified, and unusual frame residues at specific positions are sought (see, e.g., Queen et al., U.S. Pat. No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties). Several techniques known in the art are used to humanize antibodies. Such techniques include, for example, CDR-grafting (EP 239,400; PCT Publication No. WO 91 / 09967; U.S. Patent Nos. 5,225,539; 5,530,101 and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4 / 5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska et al., Proc. Natl. Sci. USA 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332, which is incorporated herein by reference in its entirety).
[0118] Fully human antibodies are particularly preferred for treating human patients. Human antibodies can be prepared by a number of methods known in the art, including bacteriophage display methods using antibody libraries derived from human immunoglobulin sequences. See also U.S. Patent Nos. 4,444,887 and 4,716,111, and PCT Publication Nos. WO 98 / 46645, WO 98 / 50433, WO 98 / 24893, WO 98 / 16654, WO 96 / 34096, WO 96 / 33735, and WO 91 / 10741, each of which is incorporated herein by reference.
[0119] Human antibodies may be produced using transgenic mice that cannot express functional endogenous immunoglobulins but can express human immunoglobulin genes. For example, a complex of human heavy and light chain immunoglobulin genes may be randomly introduced or introduced by homologous recombination into mouse embryonic stem cells. Alternatively, in addition to the human heavy and light chain genes, human variable regions, constant regions, and multivariate regions may be introduced into mouse embryonic stem cells. Human immunoglobulin loci may also be non-functionally added to the mouse heavy and light chain immunoglobulin genes, or may be introduced simultaneously, by homologous recombination. Specifically, endogenous antibody production is inhibited by homozygous deletion of the JH region. The modified embryonic stem cells are expanded and microinjected into blastocysts to generate chimeric mice. The chimeric mice are then bred to produce homozygous offspring expressing human antibodies. The transgenic mice are immunized in the usual manner with a selected antigen, for example with all or part of a desired target polypeptide. Monoclonal antibodies against the antigen can be obtained from the immunized transgenic mice by conventional hybridoma techniques. The edited human immunoglobulin genes carried by the transgenic mice are rearranged during B cell differentiation and subsequently undergo class switching and somatic mutation. Thus, the technique can be used to produce IgG, IgA, IgM and IgE antibodies that are useful for therapy. For a review of the techniques for producing human antibodies, see Lonberg and Huszar Int. Rev. Immunol. 73:65-93 (1995). For detailed descriptions of techniques for producing human antibodies and human monoclonal antibodies and technical constructs used to produce these antibodies, see, e.g., PCT Publication Nos. WO 98 / 24893; WO 96 / 34096; WO 96 / 33735; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; and 5,939,598, which are incorporated herein by reference.Additionally, companies such as Abgenix, Inc. (Freemont, Calif.) and GenPharm (San Jose, Calif.) can provide human antibodies directed against a selected antigen, generated by technology similar to that described above.
[0120] Fully human antibodies that recognize a selected antigenic epitope may be produced using a technique called "guided selection," in which a selected non-human monoclonal antibody, e.g., a murine antibody, guides the selection of a fully human antibody that recognizes the same antigenic epitope (Jespers et al., Bio / Technology 72:899-903 (1988); see also U.S. Patent No. 5,565,332, incorporated herein by reference in its entirety).
[0121] In some embodiments, DNA encoding the desired monoclonal antibody is readily isolated and sequenced by standard methods (e.g., using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of a murine antibody). A preferred source of the DNA is a hybridoma cell, either alone or subcloned. The isolated DNA may be inserted into an expression vector. The vector is then transformed into a prokaryotic or eukaryotic host cell, such as Escherichia coli (E. coli) cells, monkey COS cells, Chinese hamster ovary (CHO) cells, human embryonic kidney cells 293, or myeloma cells. These cells do not produce immunoglobulins. More specifically, antibodies can be prepared by cloning constant and variable region sequences using a single DNA (which can be synthesized as described herein), as in U.S. Pat. No. 5,658,570, filed Jan. 25, 1995, Newman et al., which is incorporated herein by reference. Essentially, this entails extracting RNA from the cells selected for this purpose, transforming it into cDNA, and amplifying it using Ig-specific primers in a PCR. Suitable primers that can be used for this purpose are also described in U.S. Patent No. 5,658,570. As discussed in more detail below, transformed cells expressing the desired antibody can be cultured in relatively large quantities to provide immunoglobulins for clinical and commercial applications.
[0122] Also, by conventional recombinant DNA techniques, one or more CDRs of the antigen-binding polypeptide of the invention can be inserted into framework regions, e.g., into human framework regions to humanize a non-human antibody. The framework regions can be naturally occurring or shared framework regions, preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278:457-479 (1998), for a list of human framework regions). Preferably, the polynucleotide resulting from the combination of the framework regions and the CDRs encodes a polypeptide that specifically binds to at least one antigen epitope (e.g., LIGHT) of the desired polypeptide. Preferably, one or more amino acid substitutions can be made within the framework regions, where the amino acid substitutions preferably improve the binding ability of the antibody to the antigen. Also, the method can result in amino acid substitutions or deletions of one or more cysteine residues of the variable regions (the cysteine residues involved in the formation of intrachain disulfide bonds). Then, an antibody molecule lacking one or more intrachain disulfide bonds can be obtained. Any other modifications made to the polynucleotide are within the scope of the present application and the prior art.
[0123] Also, techniques for producing "chimeric antibodies" by combining mouse-derived antibody molecules having appropriate antigen specificity with human antibody molecule genes having appropriate biological activity and gene splicing (Morrison et al., Proc. Natl. Acad. Sci. USA: 851-855 (1984); Neuberger et al., Nature 372: 604-608 (1984); Takeda et al., Nature 314: 452-454 (1985)) can be used. As used herein, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as an antibody comprising a murine-derived monoclonal antibody variable region and a human immunoglobulin constant region.
[0124] However, another efficient method used for the production of recombinant antibodies is disclosed by Newman, Biotechnology 10:1455-1460 (1992). Specifically, the technique produces primatized antibodies containing monkey variable domains and human constant sequences, which document is incorporated herein by reference. The technique is also described in coassigned U.S. Patent Nos. 5,658,570, 5,693,780, and 5,756,096, each of which is incorporated herein by reference.
[0125] In some embodiments, antibody-producing cell lines may be selected and cultured using techniques familiar to those skilled in the art. Such techniques are described in a variety of laboratory manuals and major publications. In this regard, techniques suitable for use herein are described in Current Protocols in Immunology, Coligan et al., eds., Green Publishing Associates And Wiley-Interscience, John Wiley and Sons, New York (1991), which is incorporated herein by reference, including supplemental references, as follows:
[0126] In some embodiments, criteria techniques known to those skilled in the art can be used to introduce mutations into the nucleotide sequence encoding the antibody of the present invention. Such mutations include, but are not limited to, site-directed mutagenesis and PCR-induced mutations to generate amino acid substitutions. Preferably, in the variants (including derivatives), the CDR-H1, CDR-H2, CDR-H3, light chain variable region, CDR-L1, CDR-L2 or CDR-L3 encodes fewer than 50 amino acid substitutions, fewer than 40 amino acid substitutions, fewer than 30 amino acid substitutions, fewer than 25 amino acid substitutions, fewer than 20 amino acid substitutions, fewer than 15 amino acid substitutions, fewer than 10 amino acid substitutions, fewer than 5 amino acid substitutions, fewer than 4 amino acid substitutions, fewer than 3 amino acid substitutions, or fewer than 2 amino acid substitutions relative to the reference variable heavy chain region. Alternatively, mutations may be introduced randomly along all or part of the coding sequence. For example, when saturation mutagenesis is used, the resulting variants can be screened for biological activity to ensure that they carry active mutations.
[0127] Treatment and diagnostic methods The antigen-binding polypeptides, variants or derivatives of the invention may be used in certain therapeutic and diagnostic methods relating to cancer or infectious diseases.
[0128] The present application also relates to antibody-based therapy, which includes administering the bispecifics of the present application to a patient, e.g., an animal, mammal, or human, to treat one or more diseases or conditions described herein. Therapeutic compounds of the present application include, but are not limited to, the antibodies of the present application (including variants and derivatives thereof as described herein) and nucleic acids or polynucleotides encoding the antibodies of the present application (including variants and derivatives thereof as described herein).
[0129] The antibodies of the present application can be used to treat, inhibit or prevent a disease, disease or condition, including a malignant disease or condition, or a condition associated with the disease or condition, e.g., a disease associated with the immune response. In some embodiments, the antibodies of the present invention can be used as an immunosuppressant. In some embodiments, the antibodies of the present invention can be used to treat an autoimmune disease. The antigen-binding polypeptides, variants or derivatives thereof of the present application can be used to inhibit the growth, progression and / or proliferation of cancers, particularly those mentioned above or in the following paragraphs.
[0130] The antibodies or variants or derivatives thereof of the present application may be used to treat, prevent, diagnose and / or predict other diseases or conditions associated with increased cell viability, including, but not limited to, cancer or tumor progression and / or progression, including malignant tumors, and associated diseases, such as multiple myeloma, lung cancer (small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma), and the like.
[0131] The specific dosage and treatment regimen used for any particular patient will depend on a variety of factors, including the particular antigen-binding polypeptide, variant or derivative thereof used, the patient's age, weight, general health, sex, diet, time of administration, excretion rate, drug combination, and the severity of the particular disease being treated. Judgment of these factors by a medical caregiver is within the ordinary skill of the art. The dosage will also depend on the individual patient being treated, the route of administration, the type of formulation, the characteristics of the compound being used, the severity of the disease and the desired effect. The dosage can be determined by principles of pharmacology and pharmacokinetics known in the art.
[0132] Methods of administering the antigen-binding polypeptide, variant or derivative thereof include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural and oral routes. The antigen-binding polypeptide or composition may be administered by any convenient route, for example, by infusion or large-volume injection, or by absorption through epithelium, mucosa or skin inner layers (e.g., oral mucosa, rectal and intestinal mucosa, etc.). It may also be administered together with other bioactive agents. Thus, pharmaceutical compositions comprising the antigen-binding polypeptide of the present application may be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (e.g., by powder, ointment, drops or transdermal patch), sublingually or bucally, or as an oral or nasal spray.
[0133] The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
[0134] Administration may be systemic or local. The antibodies of the present application may also need to be introduced into the central nervous system by any suitable route, including intrathecal and intrathecal injection. A ventricular catheter can provide ventricular injection, for example, by connecting the catheter to a reservoir. Pulmonary administration may also be achieved, for example, by formulation with an inhaler or atomizer, or a nebulizer formulation.
[0135] It may also be necessary to administer the antigen-binding polypeptides or compositions of the present application locally to the area in need of treatment. This may be accomplished, for example, by local irrigation or topical application during surgery, for example, in combination with a post-operative wound dressing, by injection, catheter, suppository, or implant, which may be porous, non-porous, or gel-like material, including films or fibers. Preferably, when administering the proteins (including antibodies) of the present application, care must be taken to use materials to which the proteins do not absorb.
[0136] The dosage of the antibodies of the present application is an amount effective to treat, inhibit, or prevent an inflammatory, immune, or malignant disorder, disease, or condition, which can be determined according to standard clinical techniques. The amount used can also be selected arbitrarily to facilitate determination of optimal dosage ranges in in vitro studies. The precise dosage to be used in a formulation will depend on the route of administration and the severity of the disease, disease, or condition, and should be determined according to the judgment of the physician and the specific circumstances of each individual patient. Effective dosages can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[0137] In one embodiment of the invention, the present invention relates to a method for treating an infectious or malignant disease, condition or condition comprising administering an antibody or variant of the antibody of the present application. The treatment is typically tested in vitro and then in vivo in an acceptable animal model for the desired therapeutic or prophylactic activity before use in humans. Suitable animal models, including genetically modified animals, are known to those of ordinary skill in the art. For example, in vitro assays for demonstrating the therapeutic effect of the antigen-binding polypeptides described herein include the effect of the antigen-binding polypeptide on a cell line or a patient tissue specimen. The effect of the antigen-binding polypeptide on a cell line and / or tissue specimen can be measured by techniques known to those of ordinary skill in the art. These techniques are, for example, assays disclosed elsewhere in this application. In vitro assays, including in vitro cell culture assays, can be used to determine whether administration of a particular antigen-binding polypeptide is indicated, including in vitro cell culture assays, in which a specimen of patient tissue is cultured in culture medium and exposed to or otherwise administered a compound, and the effect of the compound on the tissue specimen is observed.
[0138] Structural information of antibodies The structure of a monoclonal antibody is a symmetric monospecific antibody having two identical light chains and two identical heavy chains, containing light-heavy chain pairing and heavy chain-heavy chain pairing, where the light-heavy chain pairing targets the same target.
[0139] The structure of the multifunctional antibody is an asymmetric bispecific antibody having a light chain, a heavy chain and a fusion peptide, and including light-heavy chain pairing and heavy chain-fusion peptide pairing, where the light-heavy chain pairing targets a tumor antigen and the fusion peptide ScFv targets the immune cell antigen CD3.
[0140] In some cases, the heavy chain is linked to the fusion peptide by one or more disulfide bonds or one or more disulfide bonds are formed between two different fusion heavy chains, hi one embodiment, the one or more disulfide bonds are formed between amino acid residues in the hinge region between the CH1 (or VLs) and CH2 domains.
[0141] In some cases, the CH2 domain of the fusion peptide is located between the scFv fragment and the CH3 domain. In other words, the scFv fragment is linked to the CH2 end of the Fc fragment. In some cases, the single chain unit does not include a CH1 domain.
[0142] In one embodiment, either or both of the monovalent unit and the single chain unit comprise human antibody sequences or humanized sequences. For example, in one embodiment, the heavy chain of the monovalent unit comprises a human or humanized Fc fragment. In one specific embodiment, the Fc fragment of the heavy chain comprises a human IgG Fc fragment.
[0143] In one embodiment, the Fc fragment of the fusion peptide comprises a human or humanized Fc fragment. In a specific embodiment, the Fc fragment of the fusion peptide comprises a human IgG Fc fragment.
[0144] FIG. 1A is a schematic diagram of the structure of multifunctional antibody 1, and FIG. 1B is a schematic diagram of the primary protein structure of each component of the antibody.
[0145] Modified humanized anti-CD3 antibodies of the present invention (1) CDR and FR sequences of the variable regions of humanized anti-CD3 antibody
[0146] [Table 1]
[0147] (2) Sequence of a new humanized anti-CD3 antibody (partial example)
[0148] [Table 2A] [Table 2B]
[0149] Note: VHs and VLs can be paired arbitrarily.
[0150] Antibody sequence information (1) Antibodies targeting immune cell antigens
[0151] [Table 3A] [Table 3B]
[0152] (2) Antibodies targeting tumor antigens or other antigens
[0153] [Table 4]
[0154] [Table 5]
[0155] [Table 6]
[0156] [Table 7]
[0157] [Table 8]
[0158] [Table 9]
[0159] Sequences of other domains (1) Amino acid sequence of the linker domain
[0160] [Table 10]
[0161] (2) Amino acid sequence of the hinge domain
[0162] [Table 11]
[0163] (3) Amino acid sequence of the light chain constant region CL domain
[0164] [Table 12]
[0165] (4) Amino acid sequence of the heavy chain constant region CH1 domain
[0166] [Table 13]
[0167] The numbering of the Fc amino acids follows the Kabat numbering system. "Kabat numbering" refers to the numbering system described by Kabat et al., U.S. Department of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). The specific numbers are shown in the table below.
[0168] [Table 14]
[0169] Where: Amino acids 221-227 are the hinge domain; Amino acids 228-340 are the CH2 domain of the second constant region of the heavy chain; Amino acids 341-447 are the CH3 domain of the third heavy chain constant region.
[0170] Antibodies may be modified to improve heterodimer pairing efficiency. For example, in some cases, the Fc fragment of the monovalent unit heavy chain and / or the Fc fragment of the fusion peptide may contain one or more substitutions that form knob-into-hole pairs between them, compared to wild-type antibody fragments. Knob-into-hole structures are known in the art. See, for example, Ridgway et al., "'Knob-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization," Protein Engineering 9(7):617-21 (1996).
[0171] In one embodiment, T366 in one CH3 domain is substituted with a relatively large amino acid residue, such as tyrosine (Y) or tryptophan (W), and Y407 in the other CH3 domain may be substituted with a relatively small amino acid residue, such as threonine (T), alanine (A), or valine (V).
[0172] [Table 15]
[0173] In one embodiment, one of the CH3 domains contains one or more substitutions and is replaced by an amino acid residue that is positively charged under physiological conditions, and the other CH3 domain contains one or more substitutions and is replaced by one or more amino acid residues that are negatively charged under physiological conditions. In one embodiment, the positively charged amino acid residue may be arginine (R), histidine (H) or lysine (K). Meanwhile, the negatively charged amino acid residue may be aspartic acid (D) or glutamic acid (E). Optionally substituted amino acid residues include, but are not limited to, D356, L368, K392, D399 and K409.
[0174] [Table 16]
[0175] In one embodiment, one CH3 domain has S354 substituted with a cysteine and the other CH3 domain has Y349 substituted with a cysteine, forming a disulfide bond with the residues at both substituted positions.
[0176] [Table 17]
[0177] In one embodiment, one CH3 domain had H435 and Y436 substituted with arginine and phenylalanine, respectively, resulting in a significant decrease in the binding ability to Fc and Protein A. As a result, the heterodimer and homodimer have different binding activities to Protein A, allowing them to be easily separated during affinity chromatography.
[0178] [Table 18]
[0179] [Table 19]
[0180] [Table 20A] [Table 20B]
[0181] The specific sequence of the antigen
[0182] [Table 21]
[0183] [Table 22] EXAMPLES
[0184] Example 1: Humanized modified SP34 (1) SP34 sequence analysis The amino acid sequence of the SP34 heavy chain variable region (SP34VH) is as follows, in which the CDR regions are shown in bold and underlined, and the rest is the FR region.
[0185] [ka]
[0186] The amino acid sequence of the SP34 light chain variable region (SP34VL) is as follows: The CDR regions are shown in bold and underlined, and the remainder is the FR region.
[0187] [ka]
[0188] (2) Humanization (2.1) Modification of the heavy chain variable region: All commercially available fully human or humanized antibody sequences were analyzed, and the following FR sequences of heavy chain variable regions of human origin were selected. (i) FR of the first group (VHFR-1), ... means CDR.
[0189] [ka]
[0190] Alignment of SP34VH with VHFR-1. The boxes indicate the CDR regions, - indicates the region where the amino acids are identical, and * indicates that there is a difference in the amino acid at that site.
[0191] [ka]
[0192] The first group of humanized antibody VHs sequences obtained by homology analysis and conservative amino acid substitution
[0193] [ka]
[0194] (ii) FR of the second group (VHFR-2), ... means CDR.
[0195] [ka]
[0196] Alignment of SP34VH with VHFR-2. The boxes indicate the CDR regions, - indicates the area where the amino acids are identical, and * indicates that there is a difference in the amino acid at that site.
[0197] [ka]
[0198] A second group of humanized antibody VHs sequences obtained by homology analysis and conservative amino acid substitutions
[0199] [ka]
[0200] (2.2) Modification of the light chain variable region: The following FR sequences of human origin were selected: (i) The light chain variable region sequences of all commercially available fully human or humanized antibodies have been analyzed, and the first group of FRs (VLFR-1) have been obtained. ... indicates CDRs.
[0201] [ka]
[0202] Alignment of SP34VL and VLFR-1. The boxes indicate CDR regions, - indicates areas where amino acids are identical, and * indicates that there is a difference in the amino acid at that site.
[0203] [ka]
[0204] The first group of humanized antibody VLs sequences obtained by homology analysis and conservative amino acid substitutions
[0205] [ka]
[0206] (ii) A search for antibody light chain variable regions having high homology to the FRs of SP34VL was performed using NCBI-IgBlast, and a second group of FRs (VLFR-2) was obtained; ... indicates CDRs.
[0207] [ka]
[0208] Alignment of SP34VL and VLFR-2. The boxes indicate CDR regions, - indicates areas where amino acids are identical, and * indicates that there is a difference in the amino acid at that site.
[0209] [ka]
[0210] By homology analysis and conservative substitution of amino acids, the following humanized antibody VLs sequences of the second group were obtained:
[0211] [ka]
[0212] Example 2: Preparation of humanized antibodies and antibody activity assays 1. Method for constructing antibody expression plasmid The vector used is pcDNA 3.1. (1) The target fragment DNA was amplified by polymerase chain reaction (PCR). The polymerase used was DNA polymerase (2x PrimeSTAR Max Premix, TaKaRa, product number R405A). The DNA sequence was obtained by reverse translation from the amino acid sequence of SEQ ID NO: 45-73. The obtained PCR product was the target fragment DNA. (2) The vector plasmid was enzymatically digested with a restriction endonuclease, such as NotI, NruI, or BamHI-HF. The resulting enzyme digestion product is the vector DNA cut by the enzyme. *Vectors are divided into two types: heavy chain expression vectors and light chain expression vectors. Here, the heavy chain expression vector has a signal peptide and a DNA sequence of the constant region of human IGG1 heavy chain, and is composed of CH1, hinge, CH2, CH3, and heavy chain variable region. Here, the enzyme digestion site is located between the 3' end of the signal peptide and the 5' end of CH1. The light chain expression vector has a signal peptide and a DNA sequence of the constant region of human kappa light chain, and a light chain variable region, and here, the enzyme digestion site is located between the 3' end of the signal peptide and the 5' end of the light chain constant region. (3) The PCR products or enzyme digestion products were purified using a Tiangen DNA purification kit. For specific work steps, refer to the specification attached to the Tiangen kit. The obtained purification products are purified target fragment DNA and purified enzyme digested vector DNA. (4) Genetic recombination of the target fragment using recombinase (Exnase II, Vazyme, product number C112-01). The heavy chain fragment was recombined with enzyme-digested heavy chain expression vector DNA, and the light chain fragment was recombined with enzyme-digested light chain expression vector DNA. (5) Transformation by heat shock 10 μl of the recombinant product was added to 100 μl of Trans10 competent cells, mixed gently, and left in an ice bath for 30 minutes. The tube was then immersed in a 42°C water bath, held for 60 seconds, and then quickly transferred to an ice bath without shaking and held for 2 minutes. 600 μl of LB liquid medium (containing antibiotics) was added to it and cultured at 37°C for 1 hour on a rotary shaker. An appropriate amount of the bacterial liquid was applied onto an LB tablet containing the corresponding antibiotic, the tablet was inverted, and cultured overnight in a constant temperature incubator at 37°C. A single colony was picked up and sent to Wuhan genecreate Biological Engineering Co., Ltd. as a sample for sequencing. A single colony with a correct sequencer result was selected and expanded, and a large amount of plasmid was extracted and used for transfection experiments into mammalian cells. The recombinant plasmid of the heavy chain fragment and the enzyme-digested heavy chain expression vector DNA is called a heavy chain expression plasmid. The recombinant plasmid of the light chain fragment and the enzymatically digested light chain expression vector DNA is called a light chain expression plasmid.
[0213] 1. Antibody Expression Method Here, two types of transient transfection expression systems, CHO-S and 293E, were used, the details of which are as follows. (1) CHO-S transient transfection step (for example, when the total transfection volume is 100 ml) a) The day before transfection, cells are passaged (here, for example, CD-CHO can be used) to reduce the density of suspended cells to 1×10 6 The volume was adjusted to 90 ml with 100% HO cells / ml. This ensured that the cells were in logarithmic growth phase and had a cell density of 2×10 cells by the time of transfection on the second day. 6 cells / ml. b) The cells were cultured overnight on a rotary shaker at 37°C, 125 rpm, and 5% CO2. c) On the day of transfection, pre-warm the FectoPRO transfection reagent to room temperature and mix gently. d) Dilute 50 μg DNA in 10 ml of serum-free medium (e.g., opti PRO-SFM), mix gently, add to 100 μl of transfection reagent, mix evenly, and incubate at room temperature for 10 minutes to form transfection complexes. e) The transfection complex was added homogenously to 90 ml of prepared logarithmic growth phase cells, shaken immediately after addition until homogenous, and incubated on a rotary shaker at 37°C, 125 rpm, 5% CO2. f) 2-4 hours after transfection, 75 μl of transfection enhancer Fecto PRO® Booster was added. g) 18-24 hours after transfection, the temperature was lowered to 32°C and the cells were cultured. h) Materials were replenished on days 3, 5, and 7 after transfection, and the volume of the replenished materials was 3.5% of the total cell volume. i) Cells were harvested when their viability fell below 70%. Expression time was 9-13 days. (2) 293E transient transfection step (for example, when the total transfection volume is 20 ml) a) The day before transfection, cells were passaged (here, using, for example, FreeStyle TM 293 can be used), and the density of suspended cells is set to 0.6-0.8 × 10 6 The volume was adjusted to 20 ml with 100% HO cells / ml. This ensured that the cells were in logarithmic growth phase and had a cell density of 1.2-1.6 x 10 cells / ml by the time of transfection on the second day. 6 cells / ml. b) The cells were cultured overnight on a rotary shaker at 37°C, 125 rpm, and 5% CO2. c) On the day of transfection, pre-warm LPEI to room temperature and mix gently before use. d) 0.67 ml of serum-free medium (e.g., FreeStyle TM 20 μg of DNA was diluted with 20 μg of PBS and mixed thoroughly. e) 0.67 ml of serum-free medium (e.g., FreeStyle TM 293), 40 μg LPEI was diluted and mixed thoroughly; f) The LPEI diluted in step 5 was added to the DNA diluted in step 4, mixed quickly and incubated at room temperature for 15 minutes to form complexes. g) The transfection complex from step 6 was added homogenously to the prepared 20 ml of logarithmic growth phase cells. Immediately after addition, the cells were shaken until homogenous, and then cultured on a rotary shaker at 37°C, 125 rpm, and 5% CO2. h) Materials were replenished on days 1 and 3 after transfection, and the volume of the replenished materials was 5% of the total cell volume. i) Antibody was expressed and harvested by day 6. (3) The transfection was a co-transfection, in which either of the light chain expression plasmids and either of the heavy chain expression plasmids were transfected in equal proportions into the mammalian cells. The antibodies obtained by expression were monoclonal antibodies, and had a bivalent symmetric Y-shaped structure consistent with natural antibodies. A schematic diagram of the primary structure of this structure is shown in Figure 2. (4) The abbreviations of the expressed monoclonal antibodies and their expression levels (in 293E cells) are as follows.
[0214] [Table 23-1] [Table 23-2] [Table 23-3] [Table 23-4] [Table 23-5] [Table 23-6]
[0215] The B8-B57 monoclonal antibody has the same heavy chain constant region and light chain constant region, and the specific sequences are as follows:
[0216] [Table 24A] [Table 24B]
[0217] Figure 3 shows the expression levels of humanized CD3 monoclonal antibodies. As can be seen from the antibody expression levels, monoclonal antibodies B25-B33, B35-B42, B46-B53, B56-B57, etc. have expression levels of more than 15 mg / L after transient transfection.
[0218] 2. Antibody Purification The purification of antibodies has mainly been carried out by affinity chromatography, as follows: (1) Harvesting: The cell culture fluid expressing the antibody was centrifuged at 3000 x g for 10 minutes, and the supernatant was taken and filtered through a 0.22 μm filter, and stored at 4°C until it was used. (2) Affinity chromatography (MabSelect SuRe GE 17-5438-01, for example, when the column volume is 18 ml) a) Equilibration: Equilibrate the column with binding buffer (25 mM Tris / trimethylolaminomethane, pH 7.0-7.4) until the UV detector conductivity readings stabilized or remained at baseline, and equilibrate at least 5 column volumes. b) Loading: The filtered supernatant was loaded at a flow rate of 5 ml / min. c) Washing and equilibration: 5 column volumes were washed with binding buffer. d) Elution: The sample was eluted with elution buffer (50 mM citrate, pH 3.4±0.1). The sample was eluted at a flow rate of 5 ml / min for 5 column volumes, and the eluted peak was collected. e) Neutralization: The eluate was neutralized with 1 M Tris trimethylolaminomethane (pH 8.0) and the sample was adjusted to pH 6.0 ± 0.1. The antibody obtained by purification is a monoclonal antibody and has a bivalent symmetric Y-shaped structure consistent with natural antibodies. f)
[0219] 3. Antibody Activity Assay In this example, the antibody activity assay is mainly an assay of the binding activity of an antibody to CD3-positive cells. 1) Cell preparation: For the CD3 affinity test, CD3-positive induced cultured CIK cells / T cells isolated from human whole blood were used. A sufficient amount of cells was centrifuged at 300 g for 5 min, the supernatant was discarded, and the cells were resuspended in 1% FBS-PBS to a density of 4 × 10 6 50 μl was added per well, and 2 × 10 5 The cells were seeded on a plate so that each cell number was 1. The cells were centrifuged at 4° C. and 300×g for 5 minutes in a centrifuge, and the supernatant was discarded. The cells were seeded on ice. 2) Addition of antibody: Antibody was serially diluted according to the experimental design. The antibody was diluted on ice. For example, the initial concentration of the antibody was 3000 nM, and the antibody was diluted 3-fold to create an 11-fold concentration gradient. 50 μl of the diluted antibody was added to each well containing cells, gently pipetted to mix well, and incubated at 4°C for 2 hours with shaking at 1100 rpm / min. 3) Washing: The cells were resuspended in 150 μl of 1% FBS-PBS and centrifuged at 4° C. and 300×g for 5 minutes, and the supernatant was discarded. Washing was repeated once. 4) Second antibody incubation: The second antibody, PE anti-human IgG FC (Biolegend, 409304), was diluted to a final concentration of 8 μg / ml and a volume of 50 μl / well. As a control, wells were prepared to contain only cells and the second antibody, which were gently pipetted to mix well and incubated at 4°C under light protection with shaking at 1100 rpm / min for 1 h. 5) Washing: The cells were resuspended in 150 μl of 1% FBS-PBS and centrifuged at 4° C. and 300×g for 5 minutes, and the supernatant was discarded. Washing was repeated once. 6) Fixation: 200 μl of 2% paraformaldehyde was added per well to resuspend the cells, and the cells were fixed at room temperature for 20 min. The cells were centrifuged at 300×g for 5 min, and the supernatant was discarded. 7) Resuspending the cells: The cells were resuspended in 200 μl of 1% FBS-PBS, centrifuged at 300 g for 5 minutes, and the supernatant was discarded. 8) Loading into flow cytometer: The cells were resuspended in 150 μl of 1% FBS-PBS and placed into the flow cytometer for testing. 9) Data analysis: Data was analyzed using the flow cytometer analysis software FlowJo 7.6, and EC50 values were plotted and calculated using Graphpad Prism 5.
[0220] The results of detecting the binding activity of the antibodies to human and monkey T cells are shown in Figure 4. Figure 4 shows the binding ability of the monoclonal antibodies to CD3+ T cells.
[0221] As can be seen from the results of the detection of binding activity to cells, these antibodies all have higher affinity (EC50<100 nM) than the monoclonal antibody sp34, and furthermore, can bind to both human and monkey CD3.
[0222] Example 3: Preparation of multifunctional antibodies of the present invention 1. Plasmid Construction Method The procedure is the same as that in "1. Method for constructing an antibody expression plasmid" in Example 2 of the present application. Specifically, the procedure relates to the construction of three plasmids: a light chain expression plasmid (pL), a heavy chain expression plasmid (pH), and a fusion peptide expression plasmid (pF1).
[0223] The method for expressing the multifunctional antibody is the same as that described in "2. Antibody Expression Method" in Example 2 of the present application. During transfection, the three plasmids were co-transfected. To express the multifunctional antibody 1 shown in Figure 1, it is necessary to transfect and express the plasmids pL, pH and pF1 together into CHO-S or 293E cells.
[0224] The multifunctional antibody of the present invention consists of the following three polypeptides: (1) Fusion peptide: Consists of a heavy chain variable region (VHs), linker 1, light chain variable region (VLs), hinge 1, heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3-b). The sequence of linker 1 is shown in Table 10, the sequence of hinge 1 is shown in the Hin2-9 sequence in Table 11, the sequence of CH2 is shown in Table 19, and the sequence of CH3 is shown in the CH3-b sequence in Table 20. The sequences of VHs and VLs are all from the sequence of the novel humanized SP34 of the present application, and the details are shown in Table 2. (2) Heavy chain: Consists of a heavy chain variable region (VHm), heavy chain constant region 1 (CH1), hinge, heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3-a). The CH1 sequence is shown in Table 13, and the hinge sequence is shown in the Hin1 sequence in Table 11. The CH2 sequence is the same as the CH2 of the fusion peptide (shown in Table 19), and the CH3 sequence is shown in the CH3-a sequence in Table 20. CH3-a and CH3-b of the fusion peptide have a one-to-one correspondence as shown in Table 20. (3) Light chain: Consists of a light chain variable region (VLm) and a light chain constant region (CL). The sequence of CL is shown in Table 12. A schematic diagram of the structure of a multifunctional antibody is shown in FIG. 1B.
[0225] II. Purification method of multifunctional antibodies: The antibodies were purified mainly by affinity chromatography, ion exchange chromatography, hydrophobic chromatography and molecular sieves, as follows: (1) Harvesting: The cell culture fluid expressing the antibody was centrifuged at 3000 x g for 10 minutes, and the supernatant was taken and filtered through a 0.22 μm filter, and stored at 4°C until it was used. (2) Affinity chromatography (MabSelect SuRe GE 17-5438-01, for example, when the column volume is 18 ml) a) Equilibration: Equilibrate the column with binding buffer (25 mM trimethylolaminomethane, pH 7.0-7.4) until the UV detector conductivity readings stabilized or remained at baseline, and equilibrate at least 5 column volumes. b) Loading: The filtered supernatant was loaded at a flow rate of 5 ml / min. c) Washing and equilibration: 5 column volumes were washed with binding buffer. d) Elution: The sample was eluted with elution buffer (50 mM citric acid, pH 3.4±0.1) at a flow rate of 5 ml / min, over 5 column volumes, and the eluted peak was collected. e) Neutralization: The eluate was neutralized with 1M Tris / trimethylolaminomethane (pH 8.0) and the sample was adjusted to pH 6.0±0.1. (3) Ion exchange layer deposition (cation exchange chromatography as an example, HiTrap SP-HP GE 17-1151-01, column volume 5 ml) a) Sample preparation: The affinity chromatography samples were microfiltered and then diluted with ultrapure water to a conductivity of 5 mS / cm or less, and the pH was then adjusted to 6.0±0.1. b) Equilibration and loading: First, equilibrate with 5 column volumes of buffer B (25 mM citric acid + 1 M sodium chloride, conductivity should be 80-90 mS / cm, pH is 6.0 ± 0.1), then equilibrate with at least 5 column volumes of buffer A (25 mM citric acid, conductivity should be less than 5 mS / cm, pH is 6.0 ± 0.1) until conductivity, pH and UV baseline were stable, then load at a flow rate of 3 ml / min. c) Washing and equilibration: The column was washed with 5 column volumes of buffer A at a flow rate of 5 ml / min. d) Elution: 0-30% buffer B, 20 column volumes, then 100% buffer B, 10 column volumes. The flow rate was 3 ml / min throughout the entire process. The eluents were collected in different tubes for detection. (4) Hydrophobic chromatography (Capto phenyl ImpRes, filler: GE XK16 / 20 11.5 cm / 23 ml) a) Sample treatment: Samples were adjusted with 5M sodium chloride to 1M sodium chloride and the pH was adjusted to 6.0. b) Equilibration and loading: First, the column was equilibrated with 5 column volumes of Buffer A (25 mM citrate + 1 M sodium chloride, pH 6.0 ± 0.1) at a flow rate of 5 ml / min, and then loaded at a flow rate of 3.3 ml / min. c) Washing and equilibration: Wash with 5 column volumes of Buffer A at a flow rate of 5 ml / min. Wash with 5 column volumes of 10% Buffer B (25 mM citrate, pH 6.0±0.1) at a flow rate of 5 ml / min. d) Elution: Elution was performed with 90% buffer B at a flow rate of 5 ml / min, and the elution peaks were collected and detected in different tubes. (5) Molecular sieve (HiLoad Superdex 200pg GE 28989336 26 / 600) a) Equilibration and loading: After equilibration with a buffer (20 mM histidine + 0.15 M sodium chloride, pH 6.0 ± 0.1) using 2 times the column volume, the column was loaded at a flow rate of 3 ml / min. Elution: The sample was eluted with 2 column volumes of buffer, and the elution peaks were collected and detected in different tubes.
[0226] The partial abbreviations of specific expressed antibodies, and the corresponding antibody variable region amino acid sequences, are shown in the table below.
[0227] [Table 25-1] [Table 25-2] [Table 25-3] [Table 25-4] [Table 25-5] [Table 25-6] [Table 25-7] [Table 25-8] [Table 25-9] [Table 25-10] [Table 25-11] [Table 25-12] [Table 25-13] [Table 25-14] [Table 25-15] [Table 25-16] [Table 25-17] [Table 25-18] [Table 25-19] [Table 25-20] [Table 25-21] [Table 25-22] [Table 25-23]
[0228] The expression levels of the multifunctional antibody of the present invention are shown in Figure 5. Figure 5 shows the expression levels of the multifunctional antibody constructed from humanized anti-CD3 antibodies in CHO cells after transient transfection.
[0229] As can be seen from Figure 5, the expression levels of the transiently transfected CHO cells were somewhat different among the multifunctional antibodies constructed from different anti-CD3 antibodies. The expression levels of Y102, Y150-F8-3 / F8-4 / F8-6 / F8-7 / F8-8 / F8-9 / F8-10 / F9-11 / F9-12, and MS-hCD3-IC15 / IC16 / IC17 were significantly higher, with the antibody expression levels being above 40mg / L.
[0230] Example 4: Biological activity assay of multifunctional antibodies 1. Cell affinity 1) Cell preparation: CD3-positive T cells isolated from human whole blood were used to perform a CD3-terminal affinity test of multifunctional antibody molecules, and tumor cells positive for the corresponding antigen were used to perform an affinity test of tumor antigens. For example, CD38-positive MM.1S cells (purchased from the Cell Resource Center of Shanghai Institute for Life Sciences, Chinese Academy of Sciences) or RPMI 8226 cells (purchased from the Cell Resource Center of Shanghai Institute for Life Sciences, Chinese Academy of Sciences) were used for the CD38 antigen test, and PD-L1-positive H358 cells (purchased from the Cell Resource Center of Shanghai Institute for Life Sciences, Chinese Academy of Sciences) were used for the PD-L1 antigen test. A sufficient amount of cells was centrifuged at 300 × g for 5 min, the supernatant was discarded, and the cells were resuspended in 1% FBS-PBS to a density of 4 × 10 6 50 μl was added per well, and 2 × 10 5 The cells were seeded on a plate so that each cell was 1. The plate was centrifuged at 4° C. and 300×g for 5 minutes, and the supernatant was discarded. The cells were seeded on ice. 2) Addition of antibody: Antibody was serially diluted according to the experimental design. The antibody was diluted on ice. For example, the initial concentration of the antibody was 3000 nM, and it was diluted 3-fold to give 11 concentration gradients. 50 μl of the diluted antibody was added to each well containing cells, gently pipetted to mix well, and incubated at 4°C for 2 hours with shaking at 1100 rpm / min. 3) Washing: The cells were resuspended in 150 μl of 1% FBS-PBS and centrifuged at 4° C. and 300×g for 5 minutes, and the supernatant was discarded. Washing was repeated once. 4) Second antibody incubation: The second antibody, PE anti-human IgG FC (Biolegend, 409304), was diluted to a final concentration of 8ug / ml and a volume of 50μl / well. As a control, wells were prepared to contain only cells and the second antibody, which were mixed well by gentle pipetting and incubated at 4°C under light protection with shaking at 1100rpm / min for 1h. 5) Washing: The cells were resuspended in 150 μl of 1% FBS-PBS and centrifuged at 300 g for 5 minutes at 4° C. The supernatant was discarded. Washing was repeated once. 6) Fixation: 200 μl of 2% paraformaldehyde was added per well to resuspend the cells, and the cells were fixed at room temperature for 20 min. The cells were centrifuged at 300×g for 5 min, and the supernatant was discarded. 7) Cell resuspension: The cells were resuspended in 200 μl of 1% FBS-PBS and centrifuged at 300 × g for 5 min, and the supernatant was discarded; 8) Loading into flow cytometer: The cells were resuspended in 150 μl of 1% FBS-PBS and then loaded into the flow cytometer for detection. 9) Data analysis: Data was analyzed using the flow cytometer analysis software FlowJo 7.6, and Kd values were plotted and calculated using Graphpad Prism 5.
[0231] 2. T cell activation 1) Single cell suspensions were prepared from well-cultured tumor cells (non-small cell lung cancer cells H358, purchased from the Cell Resource Center of Shanghai Institutes for Life Sciences, Chinese Academy of Sciences; myeloma cells MC / CAR, purchased from ATCC) and seeded into 96-well plates at 2E4 cells / well. 2) PBMCs were isolated from whole blood of healthy volunteers by density gradient centrifugation and added to tumor cell-seeded plates according to the E:T ratio (effector cells:target cells) of the experimental design. 3) According to the experimental design, the antibody was diluted in a series of concentration steps and each concentration of antibody was added. 4) The 96-well plate was incubated in a 37°C, 5% CO2 incubator until the test time. The suspended PBMC cells were pooled together, and the corresponding CD3 and CD69 test antibodies were added. After 1 h of incubation, the excess antibodies were washed away. The cells were resuspended and the proportion of CD3 and CD69 double positive cells was detected using a flow cytometer, which was taken as the percentage of T cell activation in PBMC induced by the antibodies. Specifically, it was calculated using the following formula: Percentage of CD3 and CD69 double positive cells (%) = Number of CD3 and CD69 double positive cells / Total number of CD3 positive cells × 100% Using the "GraphPad Prism 5" software, nonlinear fitting (log(agonist) vs. response--variable slope) was performed with the bibody concentration on the horizontal axis and the CD3&CD69% value on the vertical axis to calculate the T cell activation curve and EC50 value.
[0232] 3. In vitro cytotoxicity 1) A single-cell suspension was prepared using a sufficient amount of tumor cells (e.g., H358 cells and MC / CAR cells). 2) CFSE staining of tumor cells: A certain amount of cell suspension was centrifuged (300×g, 5 min) and the supernatant was removed. CFSE solution prepared in 2 ml PBS was added so that the final concentration of CFSE was 5 μM. The cells were placed in an incubator at 5% CO2 and 37°C and incubated for 15 min. The cells were removed from the incubator, washed with PBS, and centrifuged (300×g, 5 min) to remove the supernatant. The washing was repeated three times, and the cells were resuspended in complete medium and the suspension was taken and counted. 3) Tumor cell seeding: Cell density was 2 × 10 in complete medium. 5 Resuspend the cells at 2 × 10 / ml. 4 The mixture was added to a 96-well plate at 100 μl / well. 4) Addition of effector cells, PBMC (isolated from human whole blood): Effector cells were resuspended in complete medium used for tumor cells in the experimental system, and added to the plate in the amount of effector cells corresponding to the E:T ratio of the experimental design. The addition volume was 50 μl / well. 5) Addition of diluted antibody: According to the experimental design, the highest concentration of antibody is 10μg / ml. If 50μl of antibody is added, it corresponds to 1 / 4 of the total volume of 200μl, so it is necessary to prepare each antibody at 4 times the above concentration before adding it. That is, the antibody is first diluted to 40μg / ml, and then 10-fold dilution (9 steps, volume 50μl / well) is started from 40μg / ml. 6) Observe the 96-well plate under a microscope to confirm that the cells are evenly distributed in the culture wells, then place in a cell incubator at 5% CO2 and 37°C to culture and wait for detection. 7) After the detection time was reached, the treatment for adherent cells was aspirated: the cell supernatant was aspirated, washed with 30 μl / well of PBS, the washing solution was aspirated, and combined with the previously aspirated supernatant. Trypsin was added to the cell wells at 30 μl / well, digested for 3-5 min in a cell incubator at 5% CO2 and 37°C, and the previously collected supernatant was added, and the cells in each well were pipetted until a single cell suspension was obtained. The treatment for suspended cells was: pipetted multiple times to mix evenly. 8) 10-15 min before loading into the flow cytometer, PI (final concentration 10 μg / ml) was added to each sample at 10 ul / well. 9) Flow cytometer detection: The results of the flow cytometer detection were analyzed using FlowJo software, and the data was exported to Microsoft Excel and analyzed using GraphPad. Formula for calculating killing: The percentage of CFSE and PI double positive cells among CFSE positive cells was used as the death rate of target cells. The calculation formula is as follows: Target cell mortality (%) = number of pI and CFSE double positive cells / number of CFSE positive cells x 100 10) Calculation of the killing ability of antibodies against tumor cells: The target cell death rate for all antibody concentrations was calculated using the target cell death rate calculation formula, and a curve was created with the antibody concentration on the horizontal axis and the target cell death rate on the vertical axis. Graphpad Prism 5 was used as the data analysis software, and the obtained EC50 value was regarded as the cell killing ability of the antibody.
[0233] The specific binding activities of some of the multifunctional antibodies are shown in Table 28.
[0234] The specific T cell activation abilities of some of the multifunctional antibodies are shown in FIG.
[0235] The cell killing abilities of some of the multifunctional antibodies are shown in Figures 8 and 9, and Tables 30 and 31.
[0236] Comparative Example 1: 1. Sequence alignment of humanized antibodies and existing anti-CD3 antibodies: The variable region sequences of anti-CD3 antibody 1 are described in patent US8846042B2, in which the heavy chain variable region corresponds to SEQ ID NO: 44 of said patent, and the light chain variable region corresponds to SEQ ID NO: 56 of said patent.
[0237] The variable region sequences of anti-CD3 antibody 2 are described in patent US9650446B2, in which the heavy chain variable region corresponds to SEQ ID NO:85 in said patent, and the light chain variable region corresponds to SEQ ID NO:194 in said patent.
[0238] (1) Alignment of heavy chain variable regions:
[0239] [ka]
[0240] The amino acid sequence similarity between VH2a and anti-CD3 antibody 1 VH was 96.8%, while differences were observed between FR-H1 and FR-H4.
[0241] The amino acid sequence similarity between VH2a and anti-CD3 antibody 2 VH was 95.2%, with differences observed in FR-H1, FR-H2 and CDR-H2.
[0242] (2) Alignment of the light chain variable region:
[0243] [ka]
[0244] The amino acid sequence similarity between VL5 and anti-CD3 antibody 1 VL was 94.5%, while differences were observed in FR-L1, FR-L3 and FR-L4.
[0245] The amino acid sequence similarity between VL5 and anti-CD3 antibody 2 VL was 96.3%, with differences observed in FR-L1, CDR-L1, FR-L3 and FR-L4.
[0246] 2. Comparison of biological activity between humanized antibodies and existing anti-CD3 monoclonal antibodies: (1) Affinity testing of existing anti-CD3 antibodies Table 26 Abbreviations and amino acid sequences of existing anti-CD3 antibodies
[0247] [ka] [ka]
[0248] The method for producing the existing monoclonal antibody was the same as the antibody production method in Examples 2 and 3. The data of the cell binding activity assay are shown in Figure 6. Figure 6 shows the affinity of the existing anti-CD3 monoclonal antibody to cells.
[0249] Comparative Example 2: (1) Partial abbreviations and amino acid sequences of the variable regions of comparative multifunctional antibodies More specifically, see the table below.
[0250]
Table 27-1
Table 27-2
Table 27-3
Table 27-4
Table 27-5
Table 27-6
Table 27-7
Table 27-8
Table 27-9
Table 27-10
Table 27-11
Table 27-12
Table 27-13
Table 27-14
Table 27-15
Table 27-16
[0251] (2) Affinity test of the multifunctional antibody of the present invention and the comparative multifunctional antibody with cells The affinity test results of the multifunctional antibodies are shown in the table below.
[0252] [Table 28]
[0253] From Table 28, it was observed that when the CD3 humanized antibody of the present invention is combined with a different CD38 monoclonal antibody to form a multifunctional antibody, the affinity at both ends is affected to different degrees.
[0254] (3) Testing the activation level of T cells by the multifunctional antibody of the present invention The results of testing the activation levels of human T cells for the multifunctional antibodies of the present invention, Y150-F8-9, Y150-F8-10, Y150-F8-12, Y150-F9-11, and MS-hCD3-IC-17, are shown in Figure 7 (wherein the ratio of the number of human PBMCs as effector cells to the number of MCs / CARs as target cells is 5:1, and the treatment time is 48h). Figure 7 shows the in vitro activation ability of different multifunctional antibodies of the present invention on T cells.
[0255] [Table 29]
[0256] An "*" indicates that the platform phase was not reached and the curve fitting was inaccurate. The actual EC50 values may be higher than those shown in the table.
[0257] In FIG. 7, Y150-F8-9 has the strongest T cell activation ability, and both the antibody and the binding ability to two antigens (CD38, CD3) are the strongest among the antibodies in the figure. Y150-F8-8 has a T cell activation ability at a level similar to that of Y150-F8-9 (data not shown). The antibodies Y150-F8-9, Y150-F8-10, and Y150-F8-12 have a completely matched anti-CD38 antibody sequence and a completely matched affinity for CD38, but these antibodies have an anti-CD3 antibody sequence that is not a completely matched sequence, and there are differences in affinity for CD3 due to one to three amino acid point mutations, and further, there are significant differences in the activation ability for T cells. Y150-F8-9 has the strongest T cell activation ability, followed by Y150-F8-10, and Y150-F8-12 has a weak T cell activation ability. Y150-F9-11 has significant T cell activation function.
[0258] (4) Testing the cell killing ability of the multifunctional antibody of the present invention and the comparative multifunctional antibody The test results of the killing ability of the multifunctional antibodies Y150-F8-5 and Y150-F8-6 of the present invention and the comparative multifunctional antibody Y150-F8-1 against multiple myeloma cells MC / CAR are shown in Figure 8 (wherein the ratio of the number of human PBMCs as effector cells to the number of MC / CARs as target cells is 5:1, and the treatment time is 72 h):
[0259] FIG. 8 shows the in vitro killing ability of different multifunctional antibodies against multiple myeloma cells MC / CAR.
[0260] [Table 30]
[0261] In FIG. 8, Y150-8-5 and Y150-8-6 had the same sequences of the other parts of the antibody (including Fab and Fc) as Y150-F8-1, except that the anti-CD3 scFv sequences were both novel humanized anti-CD3 antibody sequences. The anti-CD3 scFv sequence of Y150-F8-1 was the sequence of the known antibody SP34. As can be seen from the above data, the multifunctional antibody of the present invention has a tumor cell killing ability similar to or greater than that of the control antibody. Since the control antibody has no killing ability, it was shown that the cell killing ability of the multifunctional antibody is generated by bispecific targeting and binding to tumor or immune cells, inducing attack of the immune cells against the tumor cells. The CD38 monoclonal antibody is the commercially available CD38 antibody drug DARZALEX (registered trademark).
[0262] The test results of the killing ability of the multifunctional antibody Y105 of the present invention and the comparative multifunctional antibody Y106 against lung cancer cells H358 are shown in Figure 9 (wherein the ratio of the number of effector cells (human PBMC) to the number of target cells (MC / CAR) was 10:1, and the treatment time was 48 h).
[0263] FIG. 9 shows the in vitro killing ability of different multifunctional antibodies against lung cancer cell H358.
[0264] [Table 31]
[0265] In FIG. 9, except that the anti-CD3 scFv sequence of Y105 was a novel humanized anti-CD3 antibody sequence, the sequences of other parts of the antibody (including Fab and Fc) were completely the same as those of Y106. The anti-CD3 scFv sequence of Y106 was the sequence of the known antibody SP34. As can be seen from the above data, the multifunctional antibody of the present invention has a tumor cell killing ability similar to or greater than that of the control antibody. The weak killing ability of the control antibody indicates that the cell killing ability of the multifunctional antibody is generated by bispecific targeting and binding to tumor or immune cells, inducing immune cells to attack tumor cells. The S70 mAb was the commercially available PD-L1 antibody drug Tecentriq®.
[0266] (5) Stability test of the multifunctional antibody of the present invention and the comparative multifunctional antibody Test 1:40 o The thermal accelerated stability test of C. The specific work steps are as follows: 1. The sample was replaced with a specific buffer having the following composition: (a) citrate buffer: 20 mM citric acid, pH 5.5, or (b) histidine buffer: 50 mM histidine, pH 5.5, and the concentration of the sample was adjusted to 1 mg / mL. 2. Put 500μL of sample into each tube, seal it, and then o The mixture was left in a water bath at 37°C for 14 days in total. Sampling was performed every 24 hours and HPLC-SEC detection was performed.
[0267] The detection results are shown in Figures 10-16.
[0268] FIG. 10 shows the results of the multifunctional antibody Y105 of the present invention, the comparative antibody Y106, CT-F4, CT-F5 and CT-F6 at 40°C in a citrate buffer system. o10 shows the accelerated thermal stability test of C. As can be seen from FIG. 10, the multifunctional antibody of the present invention has good thermal stability. The antibody did not undergo significant changes after 14 days of 40oC treatment, which is similar to the comparative antibody Y100 and significantly superior to CT-F4, CT-F5 and CT-F6. Here, Y105 has the same Fab and Fc sequences as all the comparative antibodies, but has a different ScFv. Y105 has the anti-CD3 antibody VH2a and VL5 sequences of the present invention. Y106 is the SP34 antibody sequence, CT-F4 is the anti-CD3 antibody 1 sequence, CT-F5 is the anti-CD3 antibody 2 sequence, and CT-F6 has the anti-CD3 antibody 1 VH and anti-CD3 antibody 2 VL sequences.
[0269] FIG. 11 shows the results of the multifunctional antibodies Y150-F8-5, Y150-F8-6, Y150-F8-7, and Y150-F8-8 of the present invention and the comparative antibodies Y150-F8-1, Y150-F8-2, CT-F1, CT-F2, and CT-F3 at 40°C in a citrate buffer system. o The accelerated thermal stability test of C was shown. All the multifunctional antibodies in FIG. 11 have the same Fab sequence and the same Fc sequence between Y150-F8-5, Y150-F8-6, Y150-F8-1, CT-F1, CT-F2 and CT-F3. The anti-CD3 antibody sequences of Y150-F8-5, Y150-F8-6, Y150-F8-7 and Y150-F8-8 are VH2a and VL5, the anti-CD3 antibody sequences of Y150-F8-1 and Y150-F8-2 are SP34, the anti-CD3 antibody sequence of CT-F1 is anti-CD3 antibody 1, the anti-CD3 antibody sequence of CT-F2 is anti-CD3 antibody 2, and the anti-CD3 antibody sequence of CT-F3 is anti-CD3 antibody 1VH and anti-CD3 antibody 2VL. As can be seen from the data in the figure, the multifunctional antibodies of the present invention have significantly greater thermal stability than the comparative antibodies.
[0270] FIG. 12 shows the results of 40 h incubation in a citrate buffer system for the multifunctional antibodies Y150-F8-9, F8-10, F8-12, F9-7, and F9-11 of the present invention, and the comparative antibodies Y150-F8-1, Y150-F9-6, CT-F1, CT-F2, and CT-F3. o12 shows the accelerated thermal stability test of C. In FIG. 12, Y150-F8-9, F8-10, F8-12, F9-7, and F9-11 are multifunctional antibodies of the present invention, and their anti-CD3 antibody sequences are VH2a and VL5, or VH2j and VL5a (F8-10), or VH21 and VL5b (F8-12). Y150-F8-1, Y150-F9-6, CT-F1, CT-F2, and CT-F3 are comparative multifunctional antibodies, and their CD3 sequences are SP34 (Y150-F8-1, Y150-F9-6), anti-CD3 antibody 1 (CT-F1), anti-CD3 antibody 2 (CT-F2), anti-CD3 antibody 1 VH, and anti-CD3 antibody 2 VL (CT-F3), respectively. As can be seen from the data in FIG. 12, the multifunctional antibodies of the invention have significantly greater thermal stability than the comparative antibodies.
[0271] FIG. 13. Multifunctional antibodies MS-hCD3-IC15, IC16, IC17 and IC18 of the present invention and comparative antibodies IC-2 to IC-7. o The accelerated thermal stability test of C is shown. All antibodies in FIG. 13 have a perfect match of Fab sequences. Among them, MS-hCD3-IC15, IC16, IC17 and IC18 are multifunctional antibodies of the present invention, and their anti-CD3 antibody sequences are VH2a and VL5, or VH2j and VL5a (IC18). IC-2 to IC-7 are comparative multifunctional antibodies, and their anti-CD3 antibody sequences are SP34 (IC-2 and IC-3), anti-CD3 antibody 1 (IC-4), anti-CD3 antibody 2 (IC-5), anti-CD3 antibody 1 VH and anti-CD3 antibody 2 VL (IC-6 and IC-7), respectively. As can be seen from the data in the figure, the multifunctional antibodies of the present invention have significantly better thermal stability than the comparative antibodies.
[0272] FIG. 14 shows the results of the 40% ELISA in a histidine buffer system for the multifunctional antibodies Y150-F8-5, Y150-F8-6, Y150-F8-7, and Y150-F8-8 of the present invention and the comparative antibodies Y150-F8-1, Y150-F8-2, CT-F1, CT-F2, and CT-F3. oThe accelerated thermal stability test of C is shown. All the multifunctional antibodies in FIG. 14 have the same Fab sequence, and have the same Fc sequence between Y150-F8-5, Y150-F8-6, Y150-F8-1, CT-F1, CT-F2 and CT-F3. The anti-CD3 antibody sequences of Y150-F8-5, Y150-F8-6, Y150-F8-7 and Y150-F8-8 are VH2a and VL5, the anti-CD3 antibody sequences of Y150-F8-1 and Y150-F8-2 are SP34, the anti-CD3 antibody sequence of CT-F1 is anti-CD3 antibody 1, the anti-CD3 antibody sequence of CT-F2 is anti-CD3 antibody 2, and the anti-CD3 antibody sequence of CT-F3 is anti-CD3 antibody 1VH and anti-CD3 antibody 2VL. As can be seen from the data in the figure, all the multifunctional antibodies of the present invention have good thermal stability. The comparative antibodies Y150-F8-1, Y150-F8-2, CT-F1, CT-F2, and CT-F3 have significantly weaker thermal stability than the multifunctional antibodies of the present invention.
[0273] FIG. 15 shows the results of the 40% ELISA in a histidine buffer system for the multifunctional antibodies Y150-F8-9, F8-10, F8-12, F9-7, and F9-11 of the present invention, and the comparative antibodies Y150-F8-1, Y150-F9-6, CT-F1, CT-F2, and CT-F3. o 15 shows the accelerated thermal stability test of C. In FIG. 15, Y150-F8-9, F8-10, F8-12, F9-7, and F9-11 are multifunctional antibodies of the present invention, and their anti-CD3 antibody sequences are VH2a and VL5, or VH2j and VL5a (F8-10), or VH21 and VL5b (F8-12). Y150-F8-1, Y150-F9-6, CT-F1, CT-F2, and CT-F3 are comparative multifunctional antibodies, and their CD3 sequences are SP34 (Y150-F8-1 and Y150-F9-6), anti-CD3 antibody 1 (CT-F1), anti-CD3 antibody 2 (CT-F2), anti-CD3 antibody 1 VH, and anti-CD3 antibody 2 VL (CT-F3), respectively. As can be seen from the data in Figure 15, the multifunctional antibodies of the invention have significantly greater thermal stability than the comparative antibodies.
[0274] FIG. 16 shows the results of 40-fold increase in the activity of the multifunctional antibodies MS-hCD3-IC15, IC16, IC17, and IC18 of the present invention and comparative antibodies IC-2 to IC-7 in a histidine buffer system.o The accelerated thermal stability test of C is shown. The Fab sequences of all the antibodies in FIG. 16 were completely identical. Among them, MS-hCD3-IC15, IC16, IC17 and IC18 are multifunctional antibodies of the present invention, and their anti-CD3 antibody sequences are VH2a and VL5, or VH2j and VL5a (IC18). IC-2 to IC-7 are comparative multifunctional antibodies, and their anti-CD3 antibody sequences are SP34 (IC-2 and IC-3), anti-CD3 antibody 1 (IC-4), anti-CD3 antibody 2 (IC-5), anti-CD3 antibody 1 VH and anti-CD3 antibody 2 VL (IC-6 and IC-7), respectively. As can be seen from the data in the figure, the multifunctional antibodies of the present invention have significantly better thermal stability than the comparative antibodies.
[0275] Experiment 2: Stability study at low pH. Stability at low pH, also called acid resistance, is an index for investigating whether an antibody molecule can maintain its original state when it is neutralized to physiological conditions again after being treated in an acidic environment for a certain period of time. Specifically, in protein A affinity chromatography of antibody molecules, the antibody solution eluted in the acid elution step (using a citrate buffer of pH 3.5) is not neutralized but is maintained in the buffer for a certain period of time, and then sampled at 30 and 60 minutes, neutralized by adding 1 / 10 of the volume of 1M Tris-HCl (pH 8.0), and the HPLC-SEC test of this sample was performed.
[0276] Figure 17 shows the acid resistance stability test in a citrate buffer system at pH 3.5 for the multifunctional antibody Y105 of the present invention and the comparative antibodies Y106, CT-F4, CT-F5 and CT-F6. As can be seen from Figure 17, the multifunctional antibody of the present invention has good acid resistance. Even after treatment at low pH for 60 minutes, there was no significant change, and the antibody has significantly better acid resistance than Y106, CT-F4, CT-F5 and CT-F6.
[0277] Figure 18 shows the acid resistance stability test in a citrate buffer system at pH 3.5 for the multifunctional antibodies Y150-F8-5, Y150-F8-6, Y150-F8-7, and Y150-F8-8 of the present invention and the comparative antibodies Y150-F8-1, Y150-F8-2, CT-F1, CT-F2, and CT-F3. All the multifunctional antibodies in Figure 18 have the same Fab sequence and the same Fc sequence between Y150-F8-5, Y150-F8-6, Y150-F8-1, CT-F1, CT-F2, and CT-F3. The anti-CD3 antibody sequences of Y150-F8-5, Y150-F8-6, Y150-F8-7 and Y150-F8-8 are VH2a and VL5, the anti-CD3 antibody sequences of Y150-F8-1 and Y150-F8-2 are SP34, the anti-CD3 antibody sequence of CT-F1 is anti-CD3 antibody 1, the anti-CD3 antibody sequence of CT-F2 is anti-CD3 antibody 2, and the anti-CD3 antibody sequence of CT-F3 is anti-CD3 antibody 1VH and anti-CD3 antibody 2VL. As can be seen from the data in the figure, the multifunctional antibody of the present invention has significantly better acid resistance than the comparative antibody.
[0278] Figure 19 shows the acid resistance stability test in a citrate buffer system at pH 3.5 for the multifunctional antibodies Y150-F8-9, F8-10, F8-12, F9-7, and F9-11 of the present invention and the comparative antibodies Y150-F8-1, Y150-F9-6, CT-F1, CT-F2, and CT-F3 of the present invention. Y150-F8-9, Y150-F9-7, and Y150-F9-11 in Figure 19 are multifunctional antibodies of the present invention, and their anti-CD3 antibody sequences are VH2a and VL5, or VH2j and VL5a (F8-10), or VH2l and VL5b (F8-12). Y150-F8-1, CT-F1, CT-F2, and CT-F3 are comparative multifunctional antibodies, and their CD3 sequences are SP34 (Y150-F8-1 and Y150-F9-6), anti-CD3 antibody 1 (CT-F1), anti-CD3 antibody 2 (CT-F2), anti-CD3 antibody 1 VH, and anti-CD3 antibody 2 VL (CT-F3), respectively. As can be seen from the data in Figure 19, the multifunctional antibodies of the present invention have significantly better acid resistance than the comparative antibodies.
[0279] FIG. 20 shows the acid resistance test in a citrate buffer system at pH 3.5 for the multifunctional antibodies MS-hCD3-IC15, IC16, IC17 and IC18 of the present invention and the comparative antibodies IC-2 to IC-7. The Fab sequences of all the antibodies in FIG. 20 were completely identical. Among them, MS-hCD3-IC15, IC16, IC17 and IC18 are multifunctional antibodies of the present invention, and their anti-CD3 antibody sequences are VH2a and VL5, or VH2j and VL5a (IC18). IC-2 to IC-7 are comparative multifunctional antibodies, and their anti-CD3 antibody sequences are SP34 (IC-2 and IC-3), anti-CD3 antibody 1 (IC-4), anti-CD3 antibody 2 (IC-5), anti-CD3 antibody 1 VH and anti-CD3 antibody 2 VL (IC-6 and IC-7), respectively. As can be seen from the data in this figure, the multifunctional antibodies of the present invention have significantly superior acid resistance than the comparative antibodies.
[0280] (6) In vivo efficacy test of the multifunctional antibody of the present invention and a comparative multifunctional antibody 1. Test materials: Cells: Daudi (human multiple myeloma cell line, purchased from ATCC), human PBMC; Mouse: NOD / SCID, 5 weeks old, female, Beijing Vital River laboratory animal technology Co., Ltd.
[0281] Inoculation method: Daudi cells were inoculated subcutaneously on the right back, and human PBMCs were inoculated via the tail vein. Both Daudi and PBMC cells were inoculated on D0.
[0282] Test drugs: (B) Y150-F8-8, (C) Y150-F8-9, (D) Y150-F9-11. Negative controls: (A) blank control; (H) MS-hCD3-IC-17. Positive control: (G) CD38mAb (CD38 monoclonal antibody, Darzalex®).
[0283] Administration method: (1) Y150-F8-8, Y150-F8-9, Y150-F9-11 and MS-hCD3-17 were each designed with different doses and administered via tail vein, starting from D0, TIW (three times a week) × 2. (2) CD38mAb was administered on D0 and D7, the dose on D0 was 5mg / kg, and the dose on D7 was 15mg / kg. There were 6 mice in each group.
[0284] Body weight: Body weights were measured three times a week during the dosing period, and then twice a week.
[0285] Tumor volume: The tumor incubation period was 9-20 days, and after the average tumor volume reached 30mm3, the length and width of the tumor were measured twice a week. The monitoring time was about 30 days, or when the average tumor volume in the negative control group approached 2000mm3, all remaining tumor-bearing mice were photographed. In addition, for each group, when the tumor volume of the entire group approached 2000mm3 or when the tumor volume of a certain mouse reached 3000mm3, the group was terminated.
[0286] II. Experimental results The experimental results for Y150-F8-8 are shown in FIG. 21A, those for Y150-F8-9 are shown in FIG. 21B, and those for Y150-F9-11 are shown in FIG. 21C.
[0287] Figure 21 shows the in vivo effect and tumor volume monitoring of different multifunctional antibodies in mouse tumor models, among which Y150-F8-8 (A), F8-9 (B) and F9-11 (C) are all multifunctional antibodies of the present invention, and their anti-CD3 antibody sequences are all VH2a and VL5, and their anti-CD38 antibody sequences are different from each other.
[0288] [Table 32]
[0289] As shown in Figure 21, the multifunctional antibodies Y150-F8-8, F8-9 and F9-11 of the present invention have significant tumor-inhibiting effects, and there is no significant difference compared to the control monoclonal antibody. All of them can completely inhibit tumors at effective doses, and do not show significant toxic reactions or side effects in animals.
[0290] (7) Toxicity test of the multifunctional antibody of the present invention in monkeys 2F5mAb is an anti-CD38 antibody. It is a monoclonal antibody that can cross-react with human monkey CD38. Its specific sequence is:
[0291] [Table 33]
[0292] Toxicity tests were carried out in monkeys for the multifunctional antibodies Y150-F8-10, F9-11, and F9-12, the comparative antibody Y150-F9-6, and the monoclonal antibody 2F5mAb. A single dose was administered by intravenous infusion at the dosages shown in the table below.
[0293] [Table 34]
[0294] In the Y150-F8-10, F9-11, and F9-12 groups, the number of monkey lymphocyte subset CD38+CD20+ cells was significantly reduced until 24 h after administration, reaching complete elimination. In the 2F5mAb group (dosage: 20 mg / kg), the group cells were significantly reduced to about 30% of the pre-administration level, and were not completely eliminated. From these data, it was confirmed that the Y150-F8-10, F9-11, and F9-12 molecules have a significant CD38+ cell elimination effect, and as can be seen from Table 34, Y150-F8-10, Y150-F9-11, and Y150-F9-12 have a weaker toxicity than Y150-F9-6.
Claims
1. A humanized antibody or antigen-binding fragment thereof, specifically binds to human and / or primate, such as monkey, CD3; framework regions FR-H1, FR-H2, FR-H3, FR-H4, FR-L1, FR-L2, FR-L3 and FR-L4, and complementarity determining regions (CDRs); the amino acid sequences of CDR1 and CDR2 of the heavy chain variable region are the amino acid sequences shown in SEQ ID NOs: 1 and 2, respectively, and the amino acid sequence of CDR3 of the heavy chain variable region is any one of the sequences shown in SEQ ID NO: 3 or its variant sequences, SEQ ID NOs: 4, 10, 11, 12, 13, 14, and 191; the amino acid sequences of CDR1, CDR2, and CDR3 of the light chain variable region are set forth in SEQ ID NOs: 26, 27, and 28, respectively; The framework region of the humanized antibody comprises: a) FR-H1 of SEQ ID NO: 16 b) FR-H2 of SEQ ID NO: 17 c) FR-H3 of any one of SEQ ID NO: 23 or its variant sequences SEQ ID NO: 19, 20 and 24 d) FR-H4 of SEQ ID NO:25 e) FR-L1 of SEQ ID NO: 31 f) FR-L2 of any one of SEQ ID NO: 36 or its variant sequences SEQ ID NO: 33 and SEQ ID NO: 34 g) FR-L3 of SEQ ID NO: 41, and h) FR-L4 of SEQ ID NO: 43 A humanized antibody or antigen-binding fragment thereof comprising the sequence of:
2. comprising a heavy chain variable region and a light chain variable region, The heavy chain variable region a) the amino acid sequence of SEQ ID NO: 49 or 58, or b) an amino acid sequence having 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 49 or 58; Any one sequence selected from the group The light chain variable region comprises: d) the amino acid sequence of SEQ ID NO: 71, 72 or 73; or e) an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 71, 72 or 73. or f) the heavy chain variable region and the light chain variable region each comprise: SEQ ID NOs: 49, 71; SEQ ID NOs: 49, 73; SEQ ID NOs: 58, 72 The humanized antibody or antigen-binding fragment thereof of claim 1, comprising an amino acid sequence selected from the group consisting of:
3. A multispecific antibody, comprising: A multispecific antibody comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 2, and an antibody or antigen-binding fragment thereof against another antigen and / or another antigen epitope.
4. The following features: 1) the multispecific antibody is a bispecific antibody; 2) the other antigens and / or other antigenic epitopes are proteins that are overexpressed on tumor cells compared to corresponding non-tumor cells; 3) the other antigen and / or other antigen epitope is a tumor antigen; and 4) The other antigen and / or other antigen epitope is selected from CD38, BCMA, PD-L1, SLAMF7, Claudin 18.2 or CEA; viruses; bacteria; and endotoxins; The multispecific antibody of claim 3, having any one of the following:
5. An antibody comprising: An antibody comprising: (a) a light chain-heavy chain pair; and (b) a fusion peptide, wherein the light chain-heavy chain pair has specificity for a tumor cell or a microorganism; the fusion peptide comprises a single-chain variable region fragment and a single-chain Fc fragment, and has specificity for an immune cell; and the single-chain variable region fragment comprises a heavy chain variable region and a light chain variable region having an amino acid sequence according to any one of claims 1 to 2.
6. the Fc fragment comprises a CH2 having the sequence of any one of SEQ ID NOs: 155-161 or 192, and / or a CH3 having the sequence of any one of SEQ ID NOs: 162-183, and / or The fusion peptide comprises VHs-linker1-VLs-hinge1-CH2-CH3-b, the heavy chain comprises VHm-CH1-hinge2-CH2-CH3-a, and the light chain comprises VLm-CL; The antibody described in claim 5.
7. The light chain-heavy chain pair a) proteins that are overexpressed on tumor cells compared to corresponding non-tumor cells; b) a tumor antigen; c) viruses, d) bacteria, and / or e) endotoxin, The antibody according to any one of claims 5 to 6, which specifically binds to 8. The antibody of claim 7, wherein the tumor antigen is selected from CD38, BCMA, PD-L1, SLAMF7, Claudin 18.2 and CEA.
9. the heavy chain, the heavy chain of the fusion peptide and / or the Fc fragment of the fusion peptide comprises one or more substitutions compared to a wild-type antibody, the substitutions forming a protuberance-cavity pairing between the heavy chain and the fusion peptide; wherein T366 in one CH3 domain is substituted with tyrosine (Y) or tryptophan (W), and Y407 in the other CH3 domain is substituted with threonine (T), alanine (A) or valine (V), and / or the heavy chain and / or the Fc fragment of the fusion peptide comprises one or more substitutions, 1) the substitution forms a salt bridge pairing between the heavy chain and the fusion peptide; 2) the substitution results in the formation of a disulfide bond between the heavy chain and the fusion peptide; and / or 3) The substitution resulted in a significant decrease in the ability to bind to Fc and Protein A, in which H435 and Y436 in one CH3 domain were replaced with arginine and phenylalanine, respectively; The antibody according to any one of claims 5 to 8.
10. the VH of the fusion peptide comprises the sequence of SEQ ID NO: 49 or 58; the VL of the fusion peptide comprises the sequence of SEQ ID NO: 71, 72 or 73; Linker 1 of the fusion peptide comprises any one of SEQ ID NOs: 120-138; Hinge 1 of the fusion peptide and hinge 2 of the heavy chain comprise any one of the sequences of SEQ ID NOs: 139-147; the CH2 of the fusion peptide, the CH2 of the heavy chain comprises any one of the sequences of SEQ ID NOs: 155-161 or 192; The fusion peptide CH3-b comprises any one of SEQ ID NOs: 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183; the CH3-a of the heavy chain comprises any one of the sequences of SEQ ID NOs: 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, and 182; the VHm of the heavy chain comprises any one of SEQ ID NOs: 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 193; and wherein CH1 of the heavy chain comprises the sequence of SEQ ID NO: 154; and / or the VLm of the light chain comprises any one of SEQ ID NOs: 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 194; and / or The antibody of claim 6, wherein the CL of the light chain comprises any one of the sequences of SEQ ID NOs: 148-153.
11. The VH of the fusion peptide and the VL of the fusion peptide each comprise an amino acid sequence selected from the following group: a) SEQ ID NO: 49, 71; SEQ ID NO: 49, 73; SEQ ID NO: 58, 72 b) an amino acid sequence having 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 49 or SEQ ID NO: 58, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with the amino acid sequence of SEQ ID NO: 71, SEQ ID NO: 72 or SEQ ID NO: 73, and / or The antibody of claim 6, wherein the VHm of the heavy chain and the VLm of the light chain each comprise an amino acid sequence selected from the group consisting of: d) SEQ ID NOs: 90, 91; SEQ ID NOs: 92, 93; SEQ ID NOs: 94, 95; SEQ ID NOs: 96, 97; SEQ ID NOs: 98, 99; SEQ ID NOs: 100, 101; SEQ ID NOs: 102, 103; SEQ ID NOs: 104, 105; SEQ ID NOs: 106, 107; SEQ ID NOs: 108, 109; SEQ ID NOs: 110, 111; SEQ ID NOs: 112, 113; SEQ ID NOs: 114, 115; SEQ ID NOs: 116, 117; SEQ ID NOs: 118, 119; SEQ ID NOs: 193, 194.
12. a) the CH3-b of the fusion peptide and the CH3-a of the heavy chain have a substitution pair forming a protuberance-cavity structure, in which T366 of one CH3 domain is substituted with tyrosine (Y) or tryptophan (W), and Y407 of the other CH3 domain is substituted with threonine (T), alanine (A), or valine (V); b) the CH3-b of the fusion peptide and the CH3-a of the heavy chain have a substitution pair that forms an ionic bond; c) the CH3-b of the fusion peptide and the CH3-a of the heavy chain have a substitution pair that forms a disulfide bond; and / or d) the CH3-b of the fusion peptide and the CH3-a of the heavy chain have substitutions that result in a reduced ability to bind to Protein A, in which H435 and Y436 of one CH3 domain are replaced by arginine and phenylalanine, respectively; The antibody described in claim 6.
13. selected from Y150-F9-12, Y105, Y150-F8-5, Y150-F8-7, Y150-F8-8, Y150-F8-9, Y150-F8-10, Y150-F9-7, Y150-F9-11, MS-hCD3-IC15, MS-hCD3-IC16, MS-hCD3-IC17 and MS-hCD3-IC18; Here, the components are arranged in the following order: fusion peptide VHs-linker1-VLs-hinge1-CH2-CH3-b, heavy chain VHm-CH1-hinge2-CH2-CH3-a, light chain VLm-CL, Y150-F9-12 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 144, 192, 167, 92, 154, 139, 192, 166, 93, and 148, respectively; Y105 comprises the amino acid sequence of SEQ ID NO: 49, 129, 71, 142, 139, 167, 106, 154, 139, 159, 166, 107, 148, respectively; Y150-F8-5 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 141, 139, 167, 90, 154, 139, 157, 166, 91, and 148, respectively; Y150-F8-7 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 144, 158, 167, 90, 154, 139, 158, 166, 91, and 148, respectively; Y150-F8-8 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 144, 161, 167, 90, 154, 139, 161, 166, 91, and 148, respectively; Y150-F8-9 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 144, 161, 167, 96, 154, 139, 161, 166, 97, and 148, respectively; Y150-F8-10 comprises the amino acid sequences of SEQ ID NOs: 58, 129, 72, 144, 161, 167, 96, 154, 139, 161, 166, 97, and 148, respectively; Y150-F9-7 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 141, 139, 167, 92, 154, 139, 157, 166, 93, and 150, respectively; Y150-F9-11 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 144, 161, 167, 92, 154, 139, 161, 166, 93, and 148, respectively; MS-hCD3-IC15 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 141, 159, 167, 118, 154, 139, 159, 166, 119, and 148, respectively; MS-hCD3-IC16 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 141, 157, 167, 118, 154, 139, 157, 166, 119, and 148, respectively; MS-hCD3-IC17 comprises the amino acid sequences of SEQ ID NOs: 49, 129, 71, 141, 161, 167, 118, 154, 139, 161, 166, 119, and 148, respectively; MS-hCD3-IC18 comprises the amino acid sequences of SEQ ID NOs: 58, 129, 72, 141, 161, 167, 118, 154, 139, 161, 166, 119, 148, respectively; The antibody according to any one of claims 5 to 12.
14. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 2 and 5 to 13, about 10 -8 M or less, about 10 -8 M, 10 -9 M, 10 -10 15. An antibody or antigen-binding fragment thereof which binds to a target with a KD of about 100 nM or less, or binds to a target with an EC50 of about 100 nM or less, about 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM or less, wherein the antigen-binding fragment is selected from a fusion peptide of the antibody according to any one of claims 5 to 13, or a F(ab')2, Fab', Fab, Fv, or scFv derived from the antibody according to any one of claims 1 to 2.
15. A polynucleotide encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14.
16. An expression vector comprising the polynucleotide of claim 15.
17. 17. A host cell comprising the polynucleotide of claim 15 or the expression vector of claim 16.
18. A method for preparing the antibody according to any one of claims 1 to 14, comprising the steps of:
17. A method comprising preparing the antibody by introducing the polynucleotide of claim 15 or the expression vector of claim 16 into a host cell.
19. An antibody conjugate comprising an antibody or an antigen-binding fragment thereof described in any one of claims 1 to 14 and a conjugate portion conjugated thereto.
20. The following features: 1) the conjugate moiety is selected from a purification tag, a cytotoxic agent, a detectable label, a radioisotope, a luminescent material, a colored material, an enzyme, or polyethylene glycol; and 2) The conjugate moiety is a His tag; 20. The antibody conjugate of claim 19, having any one of the following:
21. A fusion protein comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14.
22. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, the antibody conjugate according to claim 19 or 20, or the fusion protein according to claim 21, A pharmaceutical composition optionally further comprising a pharma- ceutically acceptable carrier and / or excipient.
23. The following features: 1) is in a form suitable for oral administration to the gastrointestinal (GI) tract; 2) in a dosage form selected from tablets, capsules, pills, powders, granules, emulsions, microemulsions, solutions, suspensions, syrups and elixirs; and 3) A dosage form suitable for subcutaneous injection, intradermal injection, intravenous injection, intramuscular injection, or intralesional injection; 23. The pharmaceutical composition of claim 22, comprising any one of the following:
24. A kit comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, the antibody conjugate according to claim 19 or 20, or the fusion protein according to claim 21.
25. The following features: 1) further comprising a second antibody that specifically recognizes the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, the antibody conjugate according to claim 19 or 20, or the fusion protein according to claim 21; 2) further comprising a second antibody of 1), the second antibody further comprising a detectable label; and 3) The method further comprises the second antibody of 1), wherein the second antibody further comprises a radioisotope, a luminescent substance, a coloring substance, or an enzyme.
25. The kit of claim 24, comprising any one of the following:
26. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 for the treatment of a disease.
27. The following features: 1) the disease comprises cancer or a tumor; 2) the disease comprises multiple myeloma or lung cancer; and 3) The disease includes small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, or lung squamous cell carcinoma.
27. The antibody or antigen-binding fragment thereof of claim 26, having any one of the following:
Citation Information
Patent Citations
Multispecific Fab fusion proteins and their uses
JP2014519322A
CD3 binding molecules capable of binding to human and non human CD3
JP2017206505A
Optimized interspecies-specific bispecific single-chain antibody construct
JP2017526350A
Engineered antibodies with new world primate framework regions
WO2007019620A1
CD3 binding polypeptides
WO2013158856A2
